

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/13118 A2

(51) International Patent Classification⁷: G01N 33/574,
33/561, C12Q 1/68, C07K 14/47, C12N 5/10

(21) International Application Number: PCT/GB00/03224

(22) International Filing Date: 18 August 2000 (18.08.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
9919597.6 18 August 1999 (18.08.1999) GB

(71) Applicant (for all designated States except US): OXFORD
GLYSCSCIENCES (UK) LIMITED [GB/GB]; 10 The
Quadrant, Abingdon Science Park, Abingdon OX14 3YS
(GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): PAREKH, Rajesh,

Bhikhu [GB/GB]; Oxford GlycoSciences (UK) Ltd., 10
The Quadrant, Barton Lane, Abingdon Science Park,
Abingdon, Oxon OX14 3YS (GB). PATEL, Thakorbbhai,
Parshotambhai [GB/GB]; Oxford GlycoSciences (UK)
Ltd., 10 The Quadrant, Barton Lane, Abingdon Science
Park, Abingdon, Oxon OX14 3YS (GB). TOWNSEND,
Robert, Reid [US/GB]; Oxford GlycoSciences (UK)
Ltd., 10 The Quadrant, Barton Lane, Abingdon Science
Park, Abingdon, Oxon OX14 3YS (GB). MOYSES,
Christopher [GB/GB]; Oxford GlycoSciences (UK) Ltd.,
10 The Quadrant, Barton Lane, Abingdon Science Park,
Abingdon, Oxon OX14 3YS (GB). JOHNSON, Philip,
James [GB/CN]; The Chinese University of Hong Kong,
Dept. of Clinical Oncology, Prince of Wales Hospital,
Shatin, New Territories, Hong Kong (CN).

(74) Agents: CHAPMAN, Paul, William et al.; Kilburn &
Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

[Continued on next page]

(54) Title: METHODS AND COMPOSITIONS FOR DIAGNOSIS OF HEPATOMA



(57) Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of hepatoma, for monitoring the effectiveness of hepatoma treatment, and for drug development. Hepatoma-Diagnostic Features (HFs), detectable by two-dimensional electrophoresis of serum or plasma are described. The invention further provides Hepatoma-Diagnostic Protein Isoforms (HPIs) detectable in serum or plasma, preparations comprising isolated HPIs, antibodies immunospecific for HPIs, and kits comprising the aforesaid.

WO 01/13118 A2

BEST AVAILABLE COPY



(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— Without international search report and to be republished upon receipt of that report.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

METHODS AND COMPOSITIONS FOR DIAGNOSIS OF HEPATOMA

1. INTRODUCTION

The present invention relates to the identification of proteins and protein isoforms that are associated with hepatocellular carcinoma (hepatoma) and to their use for screening, diagnosis, prognosis, therapy and drug development.

2. BACKGROUND OF THE INVENTION

Hepatoma is an increasingly prevalent cancer, affecting several hundred thousand patients worldwide. Methods for its treatment are still relatively poor, and the main hope for more effective therapy lies in earlier and more accurate diagnosis.

Measurement of serum alphafetoprotein (AFP) is widely used in the diagnosis of hepatoma. While AFP is a useful marker when levels are markedly elevated, poor specificity and poor positive predictive value (PPV) for hepatoma at lower levels severely limit its practical application. Johnson et al., 1997, Br. J. Cancer 75: 236-240. Certain lectins show differential binding to AFP from hepatoma serum compared with AFP in benign conditions. Aoyagi et al., 1985, Biochim. Biophys. Acta 830: 217-223; Aoyagi et al., 1993, Br. J. Cancer 67: 486-492. However, these approaches have not found broad clinical acceptance. Johnson et al., *supra*. More recently, isoelectric focusing has been used to detect isoforms of AFP that appear relatively specific for hepatoma. Johnson et al., *supra*. These reports illustrate an ongoing need for identification of markers in serum for diagnosis of hepatoma.

3. SUMMARY OF THE INVENTION

The present invention provides methods and compositions for screening, diagnosis and prognosis of hepatoma, for monitoring the effectiveness of hepatoma treatment, and for drug development.

A first aspect of the invention provides methods for diagnosis of hepatoma that comprise analyzing a sample of plasma or serum by two-dimensional electrophoresis to detect the level of at least one Hepatoma-Diagnostic Feature (HF), e.g., an HF selected from the group of HFs disclosed herein. These methods are also suitable for screening, prognosis, monitoring the results of therapy, and drug development.

A second aspect of the invention provides methods for diagnosis of hepatoma that comprise detecting in a sample of plasma or serum the level of at least one Hepatoma-

diagnostic Protein Isoform (HPI), *e.g.*, an HPI selected from the group of HPIs disclosed herein. These methods are also suitable for screening, prognosis, monitoring the results of therapy, and drug development.

A third aspect of the invention provides monoclonal and polyclonal antibodies capable of immunospecific binding to an HPI, *e.g.*, an HPI disclosed herein.

A fourth aspect of the invention provides a preparation comprising an isolated HPI, *i.e.* an HPI free from proteins or protein isoforms having a significantly different isoelectric point or a significantly different apparent molecular weight from the HPI.

4. BRIEF DESCRIPTION OF THE FIGURES

Figure 1 is an image obtained from 2-dimensional electrophoresis of normal human serum, which has been annotated to identify 14 landmark features, designated PL1 to PL12 and PL15 to PL16.

5. DETAILED DESCRIPTION OF THE INVENTION

The invention described in detail below encompasses methods and compositions for screening, diagnosis and prognosis of hepatoma in a mammalian subject, methods for monitoring the results of hepatoma therapy, and methods for drug development. Preferably, the subject is human, more preferably a human adult.

For clarity of disclosure, and not by way of limitation, the invention will be described with respect to the analysis of serum samples. However, as one skilled in the art will appreciate, the assays and techniques described herein can be applied to other types of patient samples, including a body fluid (*e.g.* plasma, urine, bile, ascitic fluid), a tissue sample suspected of containing material derived from a hepatoma (*e.g.* a biopsy such as a liver biopsy or a biopsy of a suspicious mass) or homogenate thereof.

5.1. Hepatoma-Diagnostic Features (HFs)

In one aspect of the invention, two-dimensional electrophoresis is used to analyze serum from a subject in order to measure the abundance of one or more Hepatoma-Diagnostic Features (HFs) for screening or diagnosis of hepatoma, to determine the prognosis of a hepatoma patient, to monitor the effectiveness of hepatoma therapy, or for drug development. As used herein, "two-dimensional electrophoresis" (2D-electrophoresis)

means a technique comprising isoelectric focusing, followed by denaturing electrophoresis; this generates a two-dimensional gel (2D-gel) containing a plurality of separated proteins. Preferably, the step of denaturing electrophoresis uses polyacrylamide electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE). Especially preferred are the highly accurate and automatable methods and apparatus ("the Preferred Technology") described in U.S. Application No. 08/980,574 and WO 98/23950 which are incorporated herein by reference in its entirety. Briefly, the Preferred Technology provides efficient, computer-assisted methods and apparatus for identifying, selecting and characterizing biomolecules in a biological sample. A two-dimensional array is generated by separating biomolecules in a two-dimensional gel according to their electrophoretic mobility and isoelectric point. A computer-generated digital profile of the array is generated, representing the identity, apparent molecular weight, isoelectric point, and relative abundance of a plurality of biomolecules detected in the two-dimensional array, thereby permitting computer-mediated comparison of profiles from multiple biological samples, as well as computer aided excision of separated proteins of interest.

In certain instances, it may prove desirable to 'process' a biological sample before protein separation is performed with a view either to selectively enriching certain desirable proteins from within the sample or to selectively depleting the sample of certain undesirable proteins. For example, if glycosylated proteins only are of interest, such glycoproteins may be selectively isolated from a sample using lectin-affinity chromatography or lectin affinity precipitation.

Such enrichment can both enhance and simplify the subsequent protein separation and analysis. Any proteins or group of proteins carrying a structural determinant for which an antibody or other specific purification reagent is available may be so extracted, e.g. tyrosine phospho-proteins using an anti-phosphotyrosine antibody. Conversely, a sample may be depleted of specific proteins again using protein-specific affinity methods. For example, albumin may be removed from body fluids using an anti-albumin antibody, immunoglobulins may be removed using protein A or protein G (preferably immobilised). It is clear that a sample may be selectively depleted (or enriched) for more than one protein by using protein-specific reagents serially or in combination. Such enrichment/depletion can often have a beneficial effect during analysis by concentrating proteins of

interest/removing proteins that interfere with or may, for example by their predominance, limit the analysis of proteins of interest.

As used herein, the term "Hepatoma-Diagnostic Feature" (HF) refers to a feature (e.g. a spot in a 2D gel), detectable by 2D electrophoresis of a biological sample, that is differentially present in one sample compared to another, relevant sample, *e.g.*, in serum from a subject with hepatoma compared with serum from a subject without hepatoma. As used herein, a feature (or a protein isoform) is "differentially present" in a first sample with respect to a second sample when a method for detecting the feature or isoform (e.g. 2D electrophoresis or an immunoassay) reveals that the feature (or protein isoform) is present at a different relative abundance in the first sample as compared with the second sample. If the measured feature in the first sample is at a higher abundance than in the second sample, the feature or isoform is "increased" in the first sample with respect to the second; conversely, if the measured feature in the first sample is at a lower abundance than in the second sample, the feature or isoform is "decreased" in the first sample with respect to the second.

Preferably, the relative abundance of a feature in two samples is determined in two steps. First, the signal obtained upon detecting the feature in a sample is normalized by reference to a suitable background parameter, *e.g.*, to the total protein in the sample being analyzed (*e.g.*, total protein loaded onto a gel), to an invariant feature, *i.e.*, a feature whose abundance is known to be similar in the samples being compared, *e.g.*, one or more Expression Reference Features (ERFs), such as the ERFs disclosed below, or to the total signal detected from all proteins in the sample.

Secondly, the normalized signal for the feature in one sample or sample set is compared with the normalized signal for the same feature in another sample or sample set in order to identify features that are "differentially present" in the first sample (or sample set) with respect to the second.

Two groups of HFs have been identified through the methods and apparatus of the Preferred Technology. The first group consists of HFs that are decreased in the serum of subjects with hepatoma as compared with the serum of subjects without hepatoma (*e.g.* subjects with cirrhosis). These HFs can be described by apparent molecular weight (MW) and isoelectric point (pI) as follows:

Table I. HF's Decreased In Hepatoma Serum

Name	MCI	Fold decrease	pI	MW (Da)	p value
HF-1	7537	-11.7	8.12	44,093	0.0003
HF-2	7341	-4.9	6.02	62,370	0.0239
HF-3	7232	-4.6	7.60	103,154	0.0094
HF-4	7534	-3.1	7.41	44,764	0.0278
HF-5	7763	-2.7	6.93	67,555	0.0362
HF-6	7945	-2.7	5.73	57,295	0.0377
HF-7	7760	-2.5	6.37	69,194	0.0109
HF-8	7179	-2.5	5.82	166,395	0.0138
HF-9	8031	-2.1	6.15	24,467	0.0258
HF-10	7831	-2.0	7.39	37,863	0.0025
HF-11	7910	-2.0	7.79	93,302	0.1078
HF-12	7562	-2.0	5.37	40,672	0.0166
HF-13	7762	-2.0	6.41	67,826	0.1015
HF-14	7641	-2.0	6.80	28,169	0.0364
HF-57	679904	-4.6	5.90	67,315	0.0247
HF-58	679924	-2.3	6.12	69,018	0.0154
HF-59	679916	-2.1	5.80	67,315	0.001057
HF-62	680563	-1.46	7.08	23722	
HF-63	679854	-1.73	6.13	80395	0.00112
HF-64	679928	-1.59	5.75	67737	
HF-65	679935	-2.18	5.75	65450	
HF-66	679958	-1.21	6.06	61681	0.2706
HF-67	679950	-1.11	6.14	62261	0.4850
HF-68	680016	-1.16	6.65	55123	0.1796
HF-69	680040	-1.25	5.32	51786	0.3336
HF-70	680085	-1.39	5.75	47898	0.03086
HF-71	680093	-1.39	5.87	47156	0.5101

HF-72	680135	-1.29	5.31	42806	0.02175
HF-73	680175	-1.34	4.96	37545	0.02337
HF-74	680338	-1.22	5.44	25022	0.5049
HF-75	680345	-1.74	7.5	24178	0.0001741
HF-76	680524	-1.46	5.18	51865	0.04133
HF-77	680700	-1.31	7.24	114862	0.1913
HF-78	680563	-1.46	7.08	23722	
HF-79	680087	-1.39	6.14	47898	
HF-80	679971	-1.69	5.33	61297	0.09826
HF-81	680229	-1.87	5.2	32931	0.4074
HF-82	680624	-2.01	5.78	61255	0.2437
HF-83	680342	-2.61	5.22	24481	0.02259
HF-84	680371	-1.54	5.22	22851	0.00002744
HF-85	680372	-1.64	5.09	23289	0.00006081
HF-86	682292	-1.76	5.12	24646	
HF-87	680318	-5.51	5.21	25977	0.07947
HF-88	681606	-33.73	9.83	10844	
HF-89	679858	-1.42	6.06	79315	0.0007902
HF-90	679888	-1.55	4.76	73465	0.01347
HF-91	680386	-1.28	5.6	21621	0.0006296
HF-92	680446	-1.18	5.86	13845	0.5442
HF-93	680181	-1.13	5.14	37311	0.5343
HF-94	680291	-1.98	5.53	27307	0.03241
HF-95	680378	-2.17	5.76	23144	
HF-96	680406	-1.19	5.97	19045	0.3209
HF-97	680409	-1.67	5.79	18798	0.0008859
HF-98	680429	-1.14	4.47	14728	0.5350
HF-99	682264	-4.81	7.64	46831	
HF-100	679814	-1.48	6	89983	0.002941
HF-101	680036	-1.78	5.78	52437	0.07205

HF-102	680208	-1.43	5.87	34835	0.1301
HF-103	680628	-3.07	5.58	53701	0.004082

The second group consists of HFs that are increased in the serum of subjects with hepatoma as compared with the serum of subjects without hepatoma (e.g. subjects with cirrhosis). These HFs can be described by apparent molecular weight (MW) and isoelectric point (pI) as follows:

Table II. HFs Increased In Hepatoma Serum

Name	MCI	Fold increase	pI	MW (Da)	p
HF-15	7308	3.9	5.55	67,555	0.0013
HF-16	7463	3.8	7.84	50,625	0.0055
HF-17	7629	3.1	7.27	31,244	0.0000
HF-18	7366	3.0	4.60	59,928	0.0000
HF-19	7759	3.0	5.40	69,194	0.0021
HF-20	7581	3.0	4.94	38,465	0.0000
HF-21	7320	2.9	7.63	66,485	0.0009
HF-22	7690	2.9	5.72	16,707	0.0136
HF-23	7241	2.8	5.27	96,988	0.0000
HF-24	7242	2.7	5.31	96,988	0.0000
HF-25	7240	2.6	5.14	97,732	0.0000
HF-26	7734	2.6	6.04	108,311	0.0011
HF-27	7469	2.6	8.12	50,134	0.0344
HF-28	7431	2.6	5.34	52,432	0.0009
HF-29	7553	2.5	4.84	41,288	0.0000
HF-30	7457	2.5	7.61	50,822	0.0255
HF-31	7330	2.4	7.44	63,882	0.0003
HF-32	7460	2.4	7.25	50,625	0.0085
HF-33	7237	2.4	5.10	97,732	0.0000

HF-34	7243	2.4	5.21	96,988	0.0000
HF-35	7368	2.3	4.57	60168	0.0168
HF-36	7730	2.3	5.10	136,409	0.0007
HF-37	7288	2.3	6.79	71,726	0.0035
HF-38	7568	2.3	5.34	39,869	0.0034
HF-39	7238	2.3	5.04	97,732	0.0000
HF-40	7691	2.3	5.40	16,551	0.0049
HF-41	7317	2.2	6.06	66,220	0.0974
HF-42	7465	2.2	7.44	50,329	0.0097
HF-43	7380	2.2	6.01	58,044	0.0144
HF-44	7239	2.2	5.07	97,732	0.0000
HF-45	7692	2.2	6.10	16,447	0.0412
HF-46	7379	2.2	4.66	57,582	0.0040
HF-47	7180	2.2	5.36	164,341	0.0059
HF-48	7633	2.2	7.26	30,638	0.0016
HF-49	7392	2.1	5.10	56,444	0.0014
HF-50	7572	2.1	5.71	39,239	0.0227
HF-51	7190	2.0	5.26	161,308	0.0001
HF-52	7186	2.0	5.32	163,324	0.0008
HF-53	7556	2.0	5.15	40,753	0.0020
HF-54	7540	2.0	5.29	43,541	0.0004
HF-55	7185	2.0	5.22	163,324	0.0000
HF-56	7822	2.0	5.12	42,416	0.0030
HF-60	680238	2.2	7.28	31,919	0.003
HF-61	680247	2.0	7.5	30,841	0.012
HF-104	679918	1.28	4.58	65860	0.06848
HF-105	679868	1.38	8.78	76852	0.05490
HF-106	679871	1.28	8.65	75820	0.1096
HF-107	680003	2.02	6.63	57407	0.07747
HF-108	680028	1.26	6.54	52931	0.07665

HF-109	680137	2.42	4.97	42143	0.001191
HF-110	680142	2.42	4.87	41880	0.0003546
HF-111	680177	1.66	5.33	37428	0.05373
HF-112	680218	1.77	5.21	33764	0.001107
HF-113	680238	2.17	7.28	31919	0.0002972
HF-114	680280	1.13	6.85	27650	0.3030
HF-115	680418	1.99	5.71	16344	0.02678
HF-116	680425	1.95	7.03	14969	0.01694
HF-117	680653	1.83	8.25	28212	
HF-118	679939	2.07	7.74	64436	0.01761
HF-119	679972	1.9	5.28	61105	0.01859
HF-120	679757	2.29	6.72	108464	0.0001996
HF-121	679762	2.1	6.6	107212	0.0004064
HF-122	679766	1.66	6.48	104146	0.0003548
HF-123	679876	1.86	7.75	75479	0.01350
HF-124	680075	1.84	4.13	45280	0.0002768
HF-125	680124	1.13	6.75	43752	
HF-126	680244	1.73	7.67	31035	0.1775
HF-127	680250	1.45	7.28	30745	0.07981
HF-128	680427	1.29	8.35	14872	
HF-129	680599	1.63	6.82	104310	0.03921
HF-130	680783	16.39	5.43	65816	
HF-131	680815	13.63	6.96	26468	
HF-132	681676	8.81	7.7	34209	
HF-133	681924	8.92	7.02	11712	
HF-134	680362	1.25	6.59	24178	0.7421
HF-135	680171	1.22	5.13	37898	0.2304
HF-136	680275	1.22	7.89	28085	0.1920
HF-137	680424	1.38	8.34	15464	0.1933
HF-138	680476	1.25	7.33	10777	0.4495

HF-139	681923	10.69	6.81	11858	
HF-140	680147	1.4	4.88	41232	
HF-141	680101	1.2	6.65	46571	0.3139

For any given HF, the ratio obtained upon comparing the normalized signal observed upon analyzing serum from subjects with hepatoma relative to the normalized signal obtained upon analyzing serum from subjects without hepatoma will depend upon the particular analytical protocol and detection technique that is used. Accordingly, the present invention contemplates that each laboratory will establish a reference range for each HF in hepatoma-free subjects according to the analytical protocol and detection technique in use, as is conventional in the diagnostic art. Preferably, at least one positive control serum sample from a subject known to have hepatoma or at least one negative control serum sample from a subject known to be free of hepatoma (and more preferably at least one positive and at least one negative control sample) is included in each batch of test samples analyzed.

As the skilled artisan will readily appreciate, the measured MW and pI of a given feature or protein isoform will vary to some extent depending on the precise protocol used for each step of the 2D electrophoresis and for landmark matching. As used herein, the terms "MW" and "pI" are defined, respectively, to mean the apparent molecular weight and the isoelectric point of a feature or protein isoform as measured in exact accordance with the experimental protocol set forth in Section 6 below ("the Reference Protocol"). When the Reference Protocol is followed and when samples are run in duplicate or a higher number of replicates, variation in the measured mean pI of an HF or HPI is typically less than $\pm 1\%$ and variation in the measured mean MW of an HF or HPI is typically less than $\pm 5\%$. Where the skilled artisan wishes to deviate from the Reference Protocol, calibration experiments should be performed to compare the MW and pI for each HF or protein isoform as detected (a) by the Reference Protocol and (b) by the deviant protocol.

HF's can be used for detection, prognosis, diagnosis, or monitoring of hepatoma or for drug development. In one embodiment of the invention, serum from a subject is analyzed by 2D electrophoresis for quantitative detection of one or more HF's selected from the group consisting of HF-1 to HF-14, and HF-57 to HF-59, and HF-62 to HF-103 wherein a decreased abundance of an HF in serum from the subject relative to serum from a subject (or subjects) without hepatoma (*e.g.*, a control sample or a previously determined reference range) indicates the presence of hepatoma; preferably, the one or more HF's are selected from the group consisting of HF-1, HF-59, HF-75, HF-84, HF-85, HF-89, HF-91, HF-97. In another embodiment of the invention, serum from a subject is analyzed by 2D electrophoresis for quantitative detection of one or more HF's selected from the group consisting of HF-15 to HF-56 and HF-60 to HF-61, and HF-104 to 141 wherein an increased abundance of an HF in serum from the subject relative to serum from a subject (or subjects) without hepatoma (*e.g.*, a control sample or a previously determined reference range) indicates the presence of hepatoma; preferably, the one or more HF's are selected from the group consisting of HF-17, HF-18, HF-20, HF-21, HF-23, HF-24, HF-25, HF-28, HF-29, HF-31, HF-33, HF-34, HF-36, HF-39, HF-44, HF-51, HF-52, HF-54 and HF-55; HF-110, HF-113, HF-120, HF-121, HF-122, still more preferably, the one or more HF's are selected from the group consisting of HF-17, HF-18, HF-20, HF-23, HF-24, HF-25, HF-29, HF-33, HF-34, HF-39, HF-44 and HF-55.

5.2. Hepatoma-Diagnostic Protein Isoforms (HPIs)

In another aspect of the invention, serum from a subject is analyzed for quantitative detection of one or more Hepatoma-Diagnostic Protein Isoforms (HPIs) for screening or diagnosis of hepatoma, to determine the prognosis of a hepatoma patient, to monitor the effectiveness of hepatoma therapy, or for drug development. As used herein, the term "Hepatoma-Diagnostic Protein Isoform" refers to a protein isoform that is differentially present in serum subjects with hepatoma compared with serum from subjects without hepatoma. As is well known in the art, the protein product of a single gene may be expressed as variants (isoforms) (a) that differ as a result of differential post-translational modification (e.g. glycosylation, phosphorylation or acylation), so that proteins of identical amino acid sequence can differ in their pI, MW or both, and/or (b) that differ in their amino acid composition (e.g. as a result of alternative mRNA splicing or limited proteolysis). It follows that differential presence of a protein isoform does not require differential expression of the gene encoding the protein in question.

Two groups of HPIs have been identified by partial amino acid sequencing of HFs, using the methods and apparatus of the Preferred Technology. The first group consists of HPIs that are decreased in the serum of subjects with hepatoma as compared with the serum of subjects without hepatoma. The MW, pI and partial amino acid sequence of these HPIs are presented in Table III, as follows:

Table III. HPI Decreased In Hepatoma Serum

HF #	HPI	Known homologous protein	Partial amino acid sequence	pI	MW (kd)
1	HPI-1	Immunoglobulin G - H ₁ , H ₂ , H ₃	REPQVYTLPPSR	8.12	44,093
57	HPI-23	Hemopexin	DYFMPCPGR	5.90	67,315
58	HPI-24	C4 Binding Protein Alpha Chain	FSAICQGDGTWSP R	6.12	69,018
59	HPI-25	Hempexin	WLQGSQELPR	5.80	67,315

The second group comprises HPIs that are increased in the serum of subjects with hepatoma as compared with the serum of subjects without hepatoma. The MWs, pIs and

partial amino acid sequences of these HPIs are presented in Table IV as follows. For some HPIs, the partial sequence information derived from tandem mass spectrometry was not found to be described in any known public database. These are listed as 'NOVEL' in Table IV, and the partial amino acid sequence information for these HPIs is given in Table VI.

Table IV. HPIs Increased In Hepatoma Serum

HF #	HPI	Known homologous protein	Partial amino acid sequence	PI	MW (kd)
17	HPI-2	complement factor 4	RGLQDEDGYR	7.27	31,244
18	HPI-3	α_1 -anti-chymotrypsin	KITLLSALVETR	4.60	59,928
20	HPI-4	complement factor 3	KGYTQQLAFR	4.94	38,465
21	HPI-5	complement factor 3	RIPIEDGSGEVVLSR	7.63	66,485
23	HPI-6	complement factor 4	RTYNVLDMK	5.27	96,988
25	HPI-8	complement factor 4	KAEMADQASAWL TR	5.14	97,732
28	HPI-9	vitamin D-binding protein	KHLSLLTTLSNR	5.34	52,432
29	HPI-10	haptoglobin-1	RVGYVSGWGR	4.84	41,288
29	HPI-11	haptoglobin-2	KYVMLPVADQDQ CIR	4.84	41,288
31	HPI-12	complement factor 3	KTIYTPGSTVLYR	7.44	63,882
31	HPI-13	NOVEL	See Table VI	7.44	63,882
33	HPI-14	complement factor 4	RQGSFQGGFR	5.10	97,732
34	HPI-15	complement factor 4	RQGSFQGGFR	5.21	96,988
36	HPI-16	inter- α -trypsin inhibitor family heavy chain related protein	RFAHTVVTSR	5.10	136,409
39	HPI-17	complement factor 4	RQGSFQGGFR	5.04	97,732
44	HPI-18	complement factor 4	RTYNVLDMK	5.07	97,732
51	HPI-19	Ceruloplasmin	KGAYPLSIEPIGVR	5.26	161,308
52	HPI-20	Ceruloplasmin	KALYLQYTDETFR	5.32	163,324
54	HPI-21	NOVEL	See Table VI	5.29	43,541

55	HPI-22	Ceruloplasmin	RQSEDSTFYLGGER	5.22	163,324
60	HPI-26	Complement component C4A	VHYTVCIWR	7.28	31,919
61	HPI-27	Complement component C4A	CSVFYGAPSK	7.5	30,841

In one embodiment of the invention, serum from a subject is analyzed for quantitative detection of one or more HPIs selected from the group consisting of HPI-1 and HPI-23, wherein a decreased level of the one or more HPIs in serum from the subject relative to serum from a subject or subjects without hepatoma (e.g. a control sample or a previously determined reference range) indicates the presence of hepatoma. In another embodiment of the invention, serum from a subject is analyzed by 2D electrophoresis for quantitative detection of one or more HPIs selected from the group consisting of HPI-2 to HPI-22 and HPI-24, wherein an increased level of the one or more HPIs in serum from the subject relative to serum from a subject or subjects without hepatoma (e.g. a control sample or a previously determined reference range) indicates the presence of hepatoma.

As shown above, the HPIs described herein include previously unknown proteins as well as isoforms of known proteins where the isoforms were not previously known to be associated with hepatoma. For each HPI, the present invention additionally provides a preparation comprising the isolated HPI or fragments thereof, and further provides antibodies that bind to said HPI, to said fragments, or to both said HPI and said fragments. As used herein, an "isolated" HPI is an HPI free of proteins or protein isoforms having a significantly different pI or MW from those of the HPI, as determined by 2D electrophoresis. As used herein, a "significantly different" pI or MW is one that causes the contaminating protein isoform to be resolved from the HPI on 2D electrophoresis, performed according to the Reference Protocol.

In one embodiment, an isolated protein is provided, said protein comprising a peptide with the amino acid sequence identified in Table III or IV for an HPI, said protein having a pI and MW within 10% (preferably within 5%, more preferably within 1%) of the values identified in Tables III and IV for that HPI.

The HPIs of the invention can be assayed by any method known to those skilled in

the art. In one embodiment, the HPIs are separated on a 2-D gel by virtue of their MWs and pIs and visualized by staining the gel.

Alternatively, HPIs can be detected in assays, such as immunoassays, for detection, prognosis, diagnosis or monitoring of hepatoma or for drug development. In one embodiment, an immunoassay is performed by contacting a sample, derived from a subject to be tested, with an anti-HPI antibody under conditions such that immunospecific binding can occur, and detecting or measuring the amount of any immunospecific binding by the antibody. Preferably, the anti-HPI antibody preferentially binds to the HPI rather than to other isoforms of the same protein. In a preferred embodiment, the anti-HPI antibody binds to the HPI with at least 2-fold greater affinity, more preferably at least 5-fold greater affinity, still more preferably at least 10-fold greater affinity, than to other isoforms of the same protein.

In one embodiment, binding of antibody in tissue sections can be used to detect aberrant HPI localization or aberrant (*e.g.*, high, low, absent) levels of an HPI. In a specific embodiment, antibody to an HPI can be used to assay a patient tissue (*e.g.* a liver biopsy) or serum sample for the presence of the HPI where an aberrant level of HPI is indicative of hepatoma. As used herein, an "aberrant level" means an increased or decreased level relative to that present, or a standard level representing that present, in an analogous sample from a portion of the body or from a subject not having hepatoma.

The immunoassays which can be used include without limitation competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few.

If desired, an HPI can be detected by means of a two-step sandwich assay. Where an HPI represents a particular glycoform of a protein, the first step can employ an anti-HPI antibody (which can optionally be immobilized on a solid phase) to capture the HPI; in the second step, a directly or indirectly labelled lectin can be used to detect the captured HPI. Any lectin can be used for this purpose that preferentially binds to the HPI rather than (a) to other glycoforms that have the same core protein as the HPI or (b) to other isoforms that

share the antigenic determinant recognized by the antibody. In a preferred embodiment, the chosen lectin binds to the HPI with at least 2-fold greater affinity, more preferably at least 5-fold greater affinity, still more preferably at least 10-fold greater affinity, than to said other glycoforms that have the same core protein as the HPI or to said other isoforms that share the same antigenic determinant recognized by the antibody. A lectin that is suitable for detecting a given HPI can readily be identified by methods well known in the art, for instance upon testing one or more lectins enumerated in Table I on pages 158-159 of Sumar et al., *Lectins as Indicators of Disease-Associated Glycoforms*, *In: Gabius H-J & Gabius S (eds.), 1993, Lectins and Glycobiology*, at pp. 158-174 (which is incorporated herein by reference in its entirety).

If desired, a gene encoding an HPI, a related gene and related nucleic acid sequences and subsequences, including complementary sequences, can also be used in hybridization assays. A nucleotide encoding an HPI, or subsequences thereof comprising about at least 8 nucleotides (or the complement of the foregoing) can be used as hybridization probes. Hybridization assays can be used for detection, prognosis, diagnosis, or monitoring of conditions, disorders, or disease states, associated with aberrant changes in HPI gene expression, in particular hepatoma or recrudescence of hepatoma following surgical or other therapy. In a particular embodiment, such a hybridization assay is carried out by a method comprising contacting a patient sample containing nucleic acid with a nucleic acid probe capable of hybridizing to a DNA or RNA encoding an HPI, under conditions such that hybridization can occur, and detecting or measuring any resulting hybridization.

The invention also provides diagnostic kits, comprising in one or more containers an anti-HPI antibody. In addition, such a kit may optionally comprise one or more of the following: (1) instructions for using the anti-HPI antibody for diagnosis, prognosis, therapeutic monitoring, drug development or any combination of these applications; (2) a regulatory notice, i.e. a notice in the form prescribed or approved by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human testing or administration (3) a labeled binding partner to the antibody; and (4) a solid phase (such as a reagent strip) upon which the anti-HPI antibody is immobilized. If no labeled binding partner to the antibody is provided, the anti-HPI antibody itself can be labeled with a detectable marker, e.g., a chemiluminescent, enzymatic, fluorescent, or radioactive moiety.

The invention also provides a kit comprising in one or more containers a nucleic acid probe capable of hybridizing to RNA encoding a distinct HPI. In a specific embodiment, a kit can comprise in one or more containers a pair of primers (*e.g.*, each in the size range of 6-30 nucleotides, more preferably 10-20 nucleotides) that are capable of priming amplification -- such as by polymerase chain reaction (see *e.g.*, Innis et al., 1990, PCR Protocols, Academic Press, Inc., San Diego, CA), ligase chain reaction (see EP 320,308) use of Q β replicase, cyclic probe reaction, or other methods known in the art -- under appropriate reaction conditions of at least a portion of a nucleic acid encoding an HPI.

Kits are also provided which allow for the detection of a plurality of HPIs or a plurality of nucleic acids each encoding an HPI. A kit can optionally further comprise a predetermined amount of an isolated HPI protein or a nucleic acid encoding an HPI, *e.g.*, for use as a standard or control.

5.3. Use in Clinical Studies

The diagnostic methods and compositions of the present invention can assist in conducting or monitoring a clinical study, *e.g.*, for testing drugs for therapy of hepatoma. In one embodiment, candidate molecules are tested for their ability to restore HF or HPI levels in a patient suffering from hepatoma towards levels found in subjects not suffering from hepatoma or, in a treated patient (*e.g.* after surgery) to maintain HF or HPI levels at or near non-hepatoma values. The levels of one or more HF or HPIs can be assayed.

In another embodiment, the methods and compositions of the present invention are used to identify individuals with hepatoma when screening candidates for a clinical study; such individuals can then be included in or excluded from the study or can be placed in a separate cohort for treatment or analysis. If desired, the candidates can concurrently be screened to identify individuals with Hepatitis B and/or Hepatitis C; procedures for these screens are well known in the art and include, for instance, serological studies to detect antibodies to one or more Hepatitis B or Hepatitis C antigens, and PCR studies to identify one or more oligonucleotide sequences from the Hepatitis B or Hepatitis C genome.

5.4. Purification of HPIs

In particular aspects, the invention provides isolated HPIs, preferably human HPIs, and fragments and derivatives thereof which comprise an antigenic determinant (*i.e.*, can be

recognized by an antibody) or which are otherwise functionally active, as well as nucleic acid sequences encoding the foregoing. "Functionally active" HPI as used herein refers to that material displaying one or more known functional activities associated with a full-length (wild-type) HPI, *e.g.*, binding to an HPI substrate or HPI binding partner, antigenicity (binding to an anti-target antibody), immunogenicity, etc.

In specific embodiments, the invention provides fragments of an HPI comprising at least 6 amino acids, 10 amino acids, 50 amino acids, or at least 75 amino acids. Fragments, or proteins comprising fragments, lacking some or all of the regions of an HPI are also provided. Nucleic acids encoding the foregoing are provided.

Once a recombinant nucleic acid which expresses the HPI gene sequence is identified, the gene product can be analyzed. This is achieved by assays based on the physical or functional properties of the product, including radioactive labelling of the product followed by analysis by gel electrophoresis, immunoassay, etc.

Once the HPI is identified, it can be isolated and purified by standard methods including chromatography (*e.g.*, ion exchange, affinity, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins.

Alternatively, once an HPI produced by a recombinant nucleic acid is identified, the entire amino acid sequence of the HPI can be deduced from the nucleotide sequence of the chimeric gene contained in the recombinant. As a result, the protein can be synthesized by standard chemical methods known in the art (*e.g.*, see Hunkapiller, et al., 1984, *Nature* 310:105-111).

In another alternative embodiment, native HPIs can be purified from natural sources, by standard methods such as those described above (*e.g.*, immunoaffinity purification).

In a preferred embodiment, HPIs are isolated by the Preferred Technology described in U.S. Application No. 08/980,574 and WO 98/23950 which are incorporated herein by reference. For preparative-scale runs, a narrow-range "zoom gel" having a pH range of 2 pH units or less is preferred for the isoelectric focusing step, according to the method described in Westermeier, 1993, *Electrophoresis in Practice* (VCH, Weinheim, Germany), pp. 197-209 (which is incorporated herein by reference in its entirety); this modification permits a larger quantity of a target protein to be loaded onto the gel, and thereby increases the quantity of isolated HPI that can be recovered from the gel. When used in this way for

preparative-scale runs, the Preferred Technology typically provides up to 100 ng, and can provide up to 1000 ng, of an isolated HPI in a single run. Those of skill in the art will appreciate that a zoom gel can be used in any separation strategy which employs gel isoelectric focusing.

In a specific embodiment of the present invention, such HPIs, whether produced by recombinant DNA techniques or by chemical synthetic methods or by purification of native proteins, include (but are not limited to) those containing, as a primary amino acid sequence, all or part of the amino acid sequence of the HPI, as well as fragments and other derivatives, and analogs thereof, including proteins homologous thereto.

5.5. Production of Antibodies to HPIs

According to the invention, an HPI, its fragments or other derivatives, or analogs thereof, may be used as an immunogen to generate antibodies which immunospecifically bind such an immunogen. Such proteins, fragments, derivatives, or analogs can be isolated by any convenient means, including the methods described in the preceding section of this application. The antibodies generated include but are not limited to polyclonal, monoclonal, chimeric, single chain, Fab fragments, and an Fab expression library. In a specific embodiment, antibodies to a human HPI are produced. In another embodiment, antibodies to a domain of an HPI are produced. In a specific embodiment, hydrophilic fragments of an HPI are used as immunogens for antibody production.

Various procedures known in the art may be used for the production of polyclonal antibodies to an HPI or derivative or analog. In a particular embodiment, rabbit polyclonal antibodies to an epitope of an HPI, or a subsequence thereof, can be obtained. For the production of antibody, various host animals can be immunized by injection with the native HPI, or a synthetic version, or derivative (*e.g.*, fragment) thereof, including but not limited to rabbits, mice, rats, horses, goats, chickens, etc. Various adjuvants may be used to increase the immunological response, depending on the host species, and including but not limited to complete or incomplete Freund's adjuvant, mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (*bacille Calmette-Guerin*) and *Corynebacterium parvum*.

For preparation of monoclonal antibodies directed toward an HPI sequence or

analog thereof, any technique which provides for the production of antibody molecules by continuous cell lines in culture may be used. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, *Nature* 256:495-497), as well as the trioma technique, the human B-cell hybridoma technique (Kozbor et al., 1983, *Immunology Today* 4:72), and the EBV-hybridoma technique to produce human monoclonal antibodies (Cole et al., 1985, in *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96). (Each of the foregoing references is incorporated herein by reference.) In an additional embodiment of the invention, monoclonal antibodies can be produced in germ-free animals as described in PCT/US90/02545, which is incorporated herein by reference. According to the invention, human antibodies may be used and can be obtained by using human hybridomas (Cote et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:2026-2030) or by transforming human B cells with EBV virus *in vitro* (Cole et al., 1985, in Monoclonal Antibodies and Cancer Therapy, Alan R. Liss, pp. 77-96). In fact, according to the invention, techniques developed for the production of "chimeric antibodies" (Morrison et al., 1984, *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Neuberger et al., 1984, *Nature* 312:604-608; Takeda et al., 1985, *Nature* 314:452-454) by splicing the genes from a mouse antibody molecule specific for an HPI together with genes from a human antibody molecule of appropriate biological activity can be used; such antibodies are within the scope of this invention. (Each of the foregoing references is incorporated herein by reference.)

According to the invention, techniques described for the production of single chain antibodies (U.S. Patent 4,946,778, incorporated herein by reference) can be adapted to produce HPI-specific single-chain antibodies. An additional embodiment of the invention utilizes the techniques described for the construction of Fab expression libraries (Huse et al., 1989, *Science* 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity for HPIs, derivatives, or analogs.

Antibody fragments which contain the idiotype of the molecule can be generated by known techniques. For example, such fragments include but are not limited to: the F(ab')₂ fragment which can be produced by pepsin digestion of the antibody molecule; the Fab' fragments which can be generated by reducing the disulfide bridges of the F(ab')₂ fragment, the Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent, and Fv fragments.

In the production of antibodies, screening for the desired antibody can be

accomplished by techniques known in the art, *e.g.*, ELISA (enzyme-linked immunosorbent assay). For example, to select antibodies which recognize a specific domain of an HPI, one may assay generated hybridomas for a product which binds to an HPI fragment containing such a domain. For selection of an antibody that specifically binds a first HPI homolog but which does not specifically bind a different HPI homolog, one can select on the basis of positive binding to the first HPI homolog and a lack of binding to the second HPI homolog. Similarly, for selection of an antibody that specifically binds an HPI but which does not specifically bind a different isoform of the same protein (*e.g.*, a different glycoform having the same core peptide as the HPI), one can select on the basis of positive binding to the HPI and a lack of binding to the different isoform (*e.g.*, glycoform).

Antibodies specific to a domain of an HPI are also provided.

The foregoing antibodies can be used in methods known in the art relating to the localization and activity of the HPIs of the invention, *e.g.*, for imaging these proteins, measuring levels thereof in appropriate physiological samples, in diagnostic methods, etc.

5.6. Isolation Of DNA Encoding An HPI

Specific embodiments for the cloning of an HPI gene, are presented below by way of example and not of limitation.

The nucleotide sequences of the present invention, including DNA and RNA, and comprising a sequence encoding the HPI or a fragment or analog thereof, may be synthesized using methods known in the art, such as using conventional chemical approaches or polymerase chain reaction (PCR) amplification of overlapping oligonucleotides. The sequences also provide for the identification and cloning of the HPI gene from any species, for instance for screening cDNA libraries, genomic libraries or expression libraries.

The nucleotide sequences comprising a sequence encoding an HPI of the present invention are useful for their ability to selectively form duplex molecules with complementary stretches of other protein genes. Depending on the application, a variety of hybridization conditions may be employed to achieve varying sequence identities.

For a high degree of selectivity, relatively stringent conditions are used to form the duplexes, such as low salt or high temperature conditions. As used herein, "highly stringent conditions" means hybridization to filter-bound DNA in 0.5 M NaHPO₄, 7% sodium

dodecyl sulfate (SDS), 1 mM EDTA at 65°C, and washing in 0.1xSSC/0.1% SDS at 68°C (Ausubel F.M. et al., eds., 1989, *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3; incorporated herein by reference in its entirety.) For some applications, less stringent hybridization conditions are required. As used herein "moderately stringent conditions" means washing in 0.2xSSC/0.1% SDS at 42°C (Ausubel et al., 1989, *supra*). Hybridization conditions can also be rendered more stringent by the addition of increasing amounts of formamide, to destabilize the hybrid duplex. Thus, particular hybridization conditions can be readily manipulated, and will generally be chosen depending on the desired results. For example, convenient hybridization temperatures in the presence of 50% formamide are: 42°C for a probe which is 95 to 100% homologous to the HPI gene fragment, 37°C for 90 to 95% homology and 32°C for 70 to 90% homology.

In the preparation of genomic libraries, DNA fragments are generated, some of which will encode a part or the whole of an HPI. The DNA may be cleaved at specific sites using various restriction enzymes. Alternatively, one may use DNase in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication. The DNA fragments can then be separated according to size by standard

techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis, column chromatography and sucrose gradient centrifugation. The DNA fragments can then be inserted into suitable vectors, including but not limited to plasmids, cosmids, bacteriophages lambda or T₄, and yeast artificial chromosome (YAC). (See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, DNA Cloning: A Practical Approach, MRL Press, Ltd., Oxford, U.K. Vol. I, II; Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York). The genomic library may be screened by nucleic acid hybridization to labeled probe (Benton and Davis, 1977, *Science* 196:180; Grunstein and Hogness, 1975, *Proc. Natl. Acad. Sci. USA* 72:3961).

The genomic libraries may be screened with labeled degenerate oligonucleotide probes corresponding to the amino acid sequence of any peptide of the HPI using optimal approaches well known in the art. Any probe used preferably is at least 10 nucleotides (more preferably 15 nucleotides, still more preferably 20 nucleotides) in length.

As shown in Tables III and IV above, some HPIs disclosed herein correspond to previously identified proteins encoded by genes whose sequences are publicly known. To screen such a gene, any probe may be used that is complementary to the gene or its complement; preferably the probe is 10 nucleotides or longer, more preferably 15 nucleotides or longer. The Entrez database held by the National Center for Biotechnology Information (NCBI) -- which is accessible at <http://www.ncbi.nlm.nih.gov/> -- (and, for HPI-16, the NCBI non-redundant database) provides gene sequences for these HPIs under the following accession numbers, and each sequence is incorporated herein by reference:

Table V. Gene sequences of HPI-related proteins

HF #	HPI	Accession numbers
1	HPI-1	AA617854, AA630254, AA580356, AA715907, AA614684, AA580429, AA523377
17	HPI-2	U24578, M59815, M59816, K02403, AF019413
18	HPI-3	T40940, T40002
20	HPI-4	T19152, H73939, T40182, T40167, T40158, Z20894
21	HPI-5	T19152, H73939, T40182, T40167, T40158, Z20894
23	HPI-6	U24578, M59815, M59816, K02403, AF019413
25	HPI-8	U24578, M59815, M59816, K02403, AF019413
28	HPI-9	T41010, T40102, T40058, T39954
29	HPI-10	T41056, T40108, Z21017, Z20888, Z19984, Z19971
29	HPI-11	T40178, Z21027, Z19988
31	HPI-12	T19152, H73939, T40182, T40167, T40158, Z20894
33	HPI-14	U24578, M59815, M59816, K02403, AF019413
34	HPI-15	U24578, M59815, M59816, K02403, AF019413
36	HPI-16	NCBI non-redundant database published 11/22/97, Accession # 1082547
39	HPI-17	U24578, M59815, M59816, K02403, AF019413
44	HPI-18	U24578, M59815, M59816, K02403, AF019413
51	HPI-19	AA269874

52	HPI-20	AA269874
55	HPI-22	AA269874

When no nucleotide sequence is known that encodes a given BPI, degenerate probes can be used for screening. In Table VI, a degenerate set of probes is provided for each of the following HPIs: HPI-13 and HPI-21. In the method used for sequencing by mass spectroscopy in the present invention, the following sets of amino acids cannot be distinguished since they have the same mass: leucine (L) and isoleucine (I); asparagine (N) and two glycines (GG). Furthermore, the mass accuracy of the tandem mass spectrometer used for amino acid sequencing in the method of the present invention was insufficient to distinguish between the following sets of amino acids: phenylalanine (F) and oxidized methionine (M*); tryptophan (W) and the combination of aspartic acid and alanine (*i.e.* DA or AD); tryptophan (W) and the combination of glutamic acid (E) and glycine (G) (*i.e.* EG or GE); tryptophan (W) and the combination of valine (V) and serine (S) (*i.e.* VS or SV). In Table VI, each possible amino acid sequence is listed for each sequence determined by mass spectroscopy, and preferred and fully degenerate sets of probes for each possible amino acid sequence are provided.

Table VI. Amino Acid Sequences and Probes for HPIs

HF #	HPI #	Partial Amino Acid Sequence as Determined by Mass Spectrometry	Preferred Probes	Degenerate Probes
HF-31	HPI-13	AETTDF	GCCGAGACCACCGACT TC	GCNGARACNACNGAYTTY
HF-31	HPI-13	AETTDM	GCCGAGACCACCGACA TG	GCNGARACNACNGAYATG
HF-54	HPI-21	LWLGTTR	CTGTGGCTGGGCACCA CCCGC	YTNTGGYTNGGNACNACN MGN
HF-54	HPI-21	LDALGTTR		

			CTGGACGCCCTGGGCA CCACCCGC	YTNGAYGCNYTNGGNACN ACNMGN
HF-54	HPI-21	LADLGTTT	CTGGCCGACCTGGGCA CCACCCGC	YTNGCNGAYYTNGGNACN ACNMGN
HF-54	HPI-21	LGELGTTT	CTGGGCGAGCTGGGCA CCACCCGC	YTNGGNGARYTNGGNACN ACNMGN
HF-54	HPI-21	LEGLGTTT	CTGGAGGCCCTGGGCA CCACCCGC	YTNGARGGNYTNGGNACN ACNMGN
HF-54	HPI-21	LVSLGTTT	CTGGTGAGCCTGGGCAC CACCCGC	YTNGTNWSNYTNGGNACN ACNMGN
HF-54	HPI-21	LSVLGTTT	CTGAGCGTGCTGGGCAC CACCCGC	YTNWSNGTNYTNGGNACN ACNMGN
HF-54	HPI-21	IWLGTTR	ATCTGGCTGGGCACCAC CCGC	ATHTGGYTNGGNACNACN MGN
HF-54	HPI-21	IDALGTTR	ATCGACGCCCTGGGCAC CACCCGC	ATHGAYGCNYTNGGNACN ACNMGN
HF-54	HPI-21	IADLGTTT	ATCGCCGACCTGGGCAC CACCCGC	ATHGCNGAYYTNGGNACN ACNMGN
HF-54	HPI-21	IGELGTTR	ATCGGCGAGCTGGGCA CCACCCGC	ATHGGNGARYTNGGNACN ACNMGN
HF-54	HPI-21	IEGLGTTR	ATCGAGGCCCTGGGCAC CACCCGC	ATHGARGGNYTNGGNACN ACNMGN
HF-54	HPI-21	IVSLGTTR	ATCGTGAGCCTGGGCAC CACCCGC	ATHGTNWSNYTNGGNACN ACNMGN
HF-54	HPI-21	ISVLGTTR	ATCAGCGTGCTGGGCAC CACCCGC	ATHWSNGTNYTNGGNACN ACNMGN
HF-54	HPI-21	LWIGTTR	CTGTGGATCGGCACCAC CCGC	YTNTGGATHGGNACNACN MGN

HF-54	HPI-21	LDAIGTTR	CTGGACGCCATCGGCAC CACCCGC	YTNGAYGCNATHGGNACN ACNMGN
HF-54	HPI-21	LADIGTTR	CTGGCCGACATCGGCAC CACCCGC	YTNGCNGAYATHGGNACN ACNMGN
HF-54	HPI-21	LGEIGTTR	CTGGGCGAGATCGGCA CCACCCGC	YTNGNGARATHGGNACN ACNMGN
HF-54	HPI-21	LEGIGTTR	CTGGAGGCCATCGGCA CCACCCGC	YTNGARGGNATHGGNACN ACNMGN
HF-54	HPI-21	LVSIGTTR	CTGGTGAGCATCGGCA CCACCCGC	YTNGTNWSNATHGGNACN ACNMGN
HF-54	HPI-21	LSVIGTTR	CTGAGCGTGATCGGCA CCACCCGC	YTNWSNGTNATHGGNACN ACNMGN
HF-54	HPI-21	IWIGTTR	CTGTGGATCGGCACCAC CCGC	ATHTGGATHGGNACNACN MGN
HF-54	HPI-21	IDAIGTTR	ATCGACGCCATCGGCA CCACCCGC	ATHGAYGCNATHGGNACN ACNMGN
HF-54	HPI-21	IADIGTTR	ATCGCCGACATCGGCA CCACCCGC	ATHGCNGAYATHGGNACN ACNMGN
HF-54	HPI-21	IGEIGTTR	ATCGGCGAGATCGGCAC CACCCGC	ATHGGNGARATHGGNACN ACNMGN
HF-54	HPI-21	IEGIGTTR	ATCGAGGCCATCGGCAC CACCCGC	ATHGARGGNATHGGNACN ACNMGN
HF-54	HPI-21	IVSIGTTR	ATCGTGAGCATCGGCAC CACCCGC	ATHGTNWSNATHGGNACN ACNMGN
HF-54	HPI-21	ISVIGTTR	ATCAGCGTGATCGGCAC CACCCGC	ATHWSNGTNATHGGNACN ACNMGN

In Table VI, *supra*, the preferred and degenerate sets of probes are described using GCG Nucleotide Ambiguity Codes as employed in GCG SeqWeb™ sequence analysis

software (SeqWeb™ version 1.1, part of Wisconsin Package Version 10, Genetics Computer Group, Inc.) . These Nucleotide Ambiguity Codes have the following meaning:

GCG Code	Meaning
A	A
C	C
G	G
T	T
U	T
M	A or C
R	A or G
W	A or T
S	C or G
Y	C or T
K	G or T
V	A or C or G
H	A or C or T
D	A or G or T
B	C or G or T
X	G or A or T or C
N	G or A or T or C

GCG uses the letter codes for amino acid codes and nucleotide ambiguity proposed by IUPAC-IUB. These codes are compatible with the codes used by the EMBL, GenBank, and PIR databases . See IUPAC, Commission on Nomenclature of Organic Chemistry. A Guide to IUPAC Nomenclature of Organic Compounds (Recommendations 1993), Blackwell Scientific publications, 1993.

Clones in libraries with insert DNA encoding the HPI or fragments thereof will hybridize to one or more of the degenerate oligonucleotide probes (or their complement). Hybridization of such oligonucleotide probes to genomic libraries are carried out using methods known in the art. For example, hybridization with one of the above-mentioned degenerate sets of oligonucleotide probes, or their complement (or with any member of such a set, or its complement) can be performed under highly stringent or moderately stringent conditions as defined above, or can be carried out in 2X SSC, 1.0% SDS at 50°C and washed using the same conditions.

In yet another aspect, clones of nucleotide sequences encoding a part or the entire HPI or HPI-derived polypeptides may also be obtained by screening expression libraries. For example, DNA from the relevant source is isolated and random fragments are prepared

and ligated into an expression vector (e.g., a bacteriophage, plasmid, phagemid or cosmid) such that the inserted sequence in the vector is capable of being expressed by the host cell into which the vector is then introduced. Various screening assays can then be used to select for the expressed HPI or HPI-derived polypeptides. In one embodiment, the various anti-HPI antibodies of the invention can be used to identify the desired clones using methods known in the art. See, for example, Harlow and Lane, 1988, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, Appendix IV. Clones or plaques from the library are brought into contact with the antibodies to identify those clones that bind.

In an embodiment, colonies or plaques containing DNA that encodes an HPI or HPI-derived polypeptide can be detected using DYNA Beads according to Olsvick et al., 29th ICAAC, Houston, Tex. 1989, incorporated herein by reference. Anti-HPI antibodies are crosslinked to tosylated DYNA Beads M280, and these antibody-containing beads would then be used to adsorb to colonies or plaques expressing HPI or HPI-derived polypeptide. Colonies or plaques expressing an HPI or HPI-derived polypeptide are identified as any of those that bind the beads.

Alternatively, the anti-HPI antibodies can be nonspecifically immobilized to a suitable support, such as silica or Celite™ resin. This material would then be used to adsorb to bacterial colonies expressing the HPI protein or HPI-derived polypeptide as described in the preceding paragraph.

In another aspect, PCR amplification may be used to produce substantially pure DNA encoding a part of or the whole of an HPI from genomic DNA. Oligonucleotide primers, degenerate or otherwise, corresponding to known HPI sequences can be used as primers.

PCR can be carried out, e.g., by use of a Perkin-Elmer Cetus thermal cycler and a thermostable DNA polymerase such as *Thermus aquaticus* DNA polymerase (Gene Amp™ or AmpliTaq® DNA polymerase). One can choose to synthesize several different degenerate primers, for use in the PCR reactions. It is also possible to vary the stringency of hybridization conditions used in priming the PCR reactions, to allow for greater or lesser degrees of nucleotide sequence similarity between the degenerate primers and the corresponding sequences in the DNA. After successful amplification of a segment of the sequence encoding an HPI, that segment may be molecularly cloned and sequenced, and

utilized as a probe to isolate a complete genomic clone. This, in turn, will permit the determination of the gene's complete nucleotide sequence, the analysis of its expression, and the production of its protein product for functional analysis, as described *infra*.

The HPI gene can also be identified by mRNA selection by nucleic acid hybridization followed by *in vitro* translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified HPI DNA of another species (*e.g.*, mouse, human). Immunoprecipitation analysis or functional assays (*e.g.*, aggregation ability *in vitro*; binding to receptor) of the *in vitro* translation products of the isolated products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs may be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against an HPI. A radiolabelled HPI cDNA can be synthesized using the selected mRNA (from the adsorbed polysomes) as a template. The radiolabelled mRNA or cDNA may then be used as a probe to identify the HPI DNA fragments from among other genomic DNA fragments.

Alternatives to isolating HPI genomic DNA include, but are not limited to, chemically synthesizing the gene sequence itself from a known sequence or making cDNA to the mRNA which encodes the HPI. For example, RNA for cDNA cloning of the HPI gene can be isolated from cells which express the HPI. Other methods are possible and within the scope of the invention.

Any eukaryotic cell potentially can serve as the nucleic acid source for the molecular cloning of the HPI gene. The nucleic acid sequences encoding the HPI can be isolated from vertebrate, mammalian, human, porcine, bovine, feline, avian, equine, canine, as well as additional primate sources, insects, plants, etc. The DNA may be obtained by standard procedures known in the art from cloned DNA (*e.g.*, a DNA "library"), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell. (See, for example, Sambrook et al., 1989, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; Glover, D.M. (ed.), 1985, *DNA Cloning: A Practical Approach*, MRL Press, Ltd., Oxford, U.K. Vol. I, II.) Clones derived from genomic DNA may contain regulatory and intron DNA regions in addition to coding regions; clones derived from cDNA will contain only exon sequences. Whatever the source, the HPI gene should be

molecularly cloned into a suitable vector for propagation.

The identified and isolated gene or cDNA can then be inserted into an appropriate cloning vector. A large number of vector-host systems known in the art may be used. Possible vectors include, but are not limited to, plasmids or modified viruses, but the vector system must be compatible with the host cell used. Such vectors include, but are not limited to, bacteriophages such as lambda derivatives, or plasmids such as PBR322 or pUC plasmid derivatives or the Bluescript vector (Stratagene). The insertion into a cloning vector can, for example, be accomplished by ligating the DNA fragment into a cloning vector which has complementary cohesive termini. However, if the complementary restriction sites used to fragment the DNA are not present in the cloning vector, the ends of the DNA molecules may be enzymatically modified. Alternatively, any site desired may be produced by ligating nucleotide sequences (linkers) onto the DNA termini; these ligated linkers may comprise specific chemically synthesized oligonucleotides encoding restriction endonuclease recognition sequences. In an alternative method, the cleaved vector and HPI gene may be modified by homopolymeric tailing. Recombinant molecules can be introduced into host cells via transformation, transfection, infection, electroporation, etc., so that many copies of the gene sequence are generated.

In specific embodiments, transformation of host cells with recombinant DNA molecules that incorporate the isolated HPI gene, cDNA, or synthesized DNA sequence enables generation of multiple copies of the gene. Thus, the gene may be obtained in large quantities by growing transformants, isolating the recombinant DNA molecules from the transformants and, when necessary, retrieving the inserted gene from the isolated recombinant DNA.

The HPI sequences provided by the instant invention include those nucleotide sequences encoding substantially the same amino acid sequences as found in native HPis, and those encoded amino acid sequences with functionally equivalent amino acids, as well as those encoding other target derivatives or analogs.

5.7. Expression of DNA Encoding HPis

The nucleotide sequence encoding an HPI or a functionally active analog or fragment or other derivative thereof can be inserted into an appropriate expression vector, *i.e.*, a vector which contains the necessary elements for the transcription and translation of

the inserted protein-coding sequence. The necessary transcriptional and translational signals can also be supplied by the native HPI gene or its flanking regions. A variety of host-vector systems may be utilized to express the protein-coding sequence. These include but are not limited to mammalian cell systems infected with virus (*e.g.*, vaccinia virus, adenovirus, etc.); insect cell systems infected with virus (*e.g.*, baculovirus); microorganisms such as yeast containing yeast vectors, or bacteria transformed with bacteriophage, DNA, plasmid DNA, or cosmid DNA. The expression elements of vectors vary in their strengths and specificities. Depending on the host-vector system utilized, any one of a number of suitable transcription and translation elements may be used. In specific embodiments, the human HPI gene is expressed, or a sequence encoding a functionally active portion of the human HPI. In yet another embodiment, a fragment of target comprising a domain of the HPI is expressed.

Any of the methods previously described for the insertion of DNA fragments into a vector may be used to construct expression vectors containing a chimeric gene consisting of appropriate transcriptional and translational control signals and the protein coding sequences. These methods may include *in vitro* recombinant DNA and synthetic techniques and *in vivo* recombinants (genetic recombination). Expression of nucleic acid sequence encoding an HPI or peptide fragment may be regulated by a second nucleic acid sequence so that the HPI or peptide is expressed in a host transformed with the recombinant DNA molecule. For example, expression of an HPI gene may be controlled by any promoter or enhancer element known in the art. Promoters which may be used to control HPI gene expression include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, 1981, *Nature* 290:304-310), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto, et al., 1980, *Cell* 22:787-797), the herpes thymidine kinase promoter (Wagner et al., 1981, *Proc. Natl. Acad. Sci. USA* 78:1441-1445), the regulatory sequences of the metallothionein gene (Brinster et al., 1982, *Nature* 296:39-42); prokaryotic expression vectors such as the β -lactamase promoter (Villa-Komaroff, et al., 1978, *Proc. Natl. Acad. Sci. USA* 75:3727-3731), or the *tac* promoter (DeBoer, et al., 1983, *Proc. Natl. Acad. Sci. USA* 80:21-25); see also "Useful proteins from recombinant bacteria" in *Scientific American*, 1980, 242:74-94; plant expression vectors comprising the nopaline synthetase promoter region (Herrera-Estrella et al., *Nature* 303:209-213) or the cauliflower mosaic virus 35S RNA promoter (Gardner, et al., 1981, *Nucl. Acids Res.* 9:2871), and the

promoter of the photosynthetic enzyme ribulose biphosphate carboxylase (Herrera-Estrella et al., 1984, *Nature* 310:115-120); promoter elements from yeast or other fungi such as the Gal 4 promoter, the ADC (alcohol dehydrogenase) promoter, PGK (phosphoglycerol kinase) promoter, alkaline phosphatase promoter, and the following animal transcriptional control regions, which exhibit tissue specificity and have been utilized in transgenic animals: elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, *Cell* 38:639-646; Ornitz et al., 1986, *Cold Spring Harbor Symp. Quant. Biol.* 50:399-409; MacDonald, 1987, *Hepatology* 7:425-515); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, *Nature* 315:115-122), immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, *Cell* 38:647-658; Adames et al., 1985, *Nature* 318:533-538; Alexander et al., 1987, *Mol. Cell. Biol.* 7:1436-1444), mouse mammary tumor virus control region which is active in testicular, breast, lymphoid and mast cells (Leder et al., 1986, *Cell* 45:485-495), albumin gene control region which is active in liver (Pinkert et al., 1987, *Genes and Devel.* 1:268-276), alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, *Mol. Cell. Biol.* 5:1639-1648; Hammer et al., 1987, *Science* 235:53-58; alpha 1-antitrypsin gene control region which is active in the liver (Kelsey et al., 1987, *Genes and Devel.* 1:161-171), beta-globin gene control region which is active in myeloid cells (Mogam et al., 1985, *Nature* 315:338-340; Kollias et al., 1986, *Cell* 46:89-94; myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, *Cell* 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Sani, 1985, *Nature* 314:283-286), and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, *Science* 234:1372-1378).

In a specific embodiment, a vector is used that comprises a promoter operably linked to an HPI-encoding nucleic acid, one or more origins of replication, and, optionally, one or more selectable markers (*e.g.*, an antibiotic resistance gene).

In a specific embodiment, an expression construct is made by subcloning an HPI coding sequence into the *EcoRI* restriction site of each of the three pGEX vectors (Glutathione S-Transferase expression vectors; Smith and Johnson, 1988, *Gene* 7:31-40). This allows for the expression of the HPI product from the subclone in the correct reading frame.

Expression vectors containing HPI gene inserts can be identified by three general

approaches: (a) nucleic acid hybridization, (b) presence or absence of "marker" gene functions, and (c) expression of inserted sequences. In the first approach, the presence of an HPI gene inserted in an expression vector can be detected by nucleic acid hybridization using probes comprising sequences that are homologous to an inserted HPI gene. In the second approach, the recombinant vector/host system can be identified and selected based upon the presence or absence of certain "marker" gene functions (*e.g.*, thymidine kinase activity, resistance to antibiotics, transformation phenotype, occlusion body formation in baculovirus, etc.) caused by the insertion of an HPI gene in the vector. For example, if the HPI gene is inserted within the marker gene sequence of the vector, recombinants containing the HPI gene insert can be identified by the absence of the marker gene function. In the third approach, recombinant expression vectors can be identified by assaying the HPI gene product expressed by the recombinant. Such assays can be based, for example, on the physical or functional properties of the HPI gene product in *in vitro* assay systems, *e.g.*, binding with anti-HPI antibody.

Once a particular recombinant DNA molecule is identified and isolated, several methods known in the art may be used to propagate it. Once a suitable host system and growth conditions are established, recombinant expression vectors can be propagated and prepared in quantity. As previously explained, the expression vectors which can be used include, but are not limited to, the following vectors or their derivatives: human or animal viruses such as vaccinia virus or adenovirus; insect viruses such as baculovirus; yeast vectors; bacteriophage vectors (*e.g.*, lambda), and plasmid and cosmid DNA vectors, to name but a few.

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Expression from certain promoters can be elevated in the presence of certain inducers; thus, expression of the genetically engineered HPI may be controlled. Furthermore, different host cells have characteristic and specific mechanisms for the translational and post-translational processing and modification (*e.g.*, glycosylation, phosphorylation of proteins). Appropriate cell lines or host systems can be chosen to ensure the desired modification and processing of the foreign protein expressed. For example, expression in a bacterial system can be used to produce an unglycosylated core protein product. Expression in yeast will produce a glycosylated product. Expression in

mammalian cells can be used to ensure "native" glycosylation of a heterologous protein. Furthermore, different vector/host expression systems may affect processing reactions to different extents.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the differentially expressed or pathway gene protein may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the differentially expressed or pathway gene protein. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the differentially expressed or pathway gene protein.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy et al., 1980, Cell 22:817) genes can be employed in tk⁻, hgprt⁻ or apt⁻ cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, Gene 30:147) genes.

In other specific embodiments, the HPI, fragment, analog, or derivative may be expressed as a fusion, or chimeric protein product (comprising the protein, fragment, analog, or derivative joined via a peptide bond to a heterologous protein sequence (of a different protein)). Such a chimeric product can be made by ligating the appropriate nucleic

acid sequences encoding the desired amino acid sequences to each other by methods known in the art, in the proper coding frame, and expressing the chimeric product by methods commonly known in the art. Alternatively, such a chimeric product may be made by protein synthetic techniques, *e.g.*, by use of a peptide synthesizer.

Both cDNA and genomic sequences can be cloned and expressed.

6. EXAMPLE: PROTEINS FROM SERUM OF PATIENTS WITH AND WITHOUT HEPATOMA

Using the following Reference Protocol, proteins in serum from 33 patients with hepatoma and 19 patients with cirrhosis of the liver were separated by isoelectric focusing followed by SDS-PAGE and analyzed. Each sample was run in duplicate.

6.1. Sample preparation

A protein assay was carried out on the serum sample as received (Pierce BCA Cat # 23225). A volume of serum corresponding to 300µg of total protein was aliquoted and an equal volume of 10% (w/v) SDS (Fluka 71729), 2.3% (w/v) dithiothreitol (BDH 443852A) was added. The sample was heated at 95°C for 5 mins, and then allowed to cool to 20°C. 125µl of the following buffer was then added to the sample:

8M urea (BDH 452043w)
4% CHAPS (Sigma C3023)
65mM dithiothreitol (DTT)
2% (v/v) Resolytes 3.5-10 (BDH 44338 2x)

This mixture was vortexed, and centrifuged at 13000 rpm for 5 mins at 15°C, and the supernatant was analyzed by isoelectric focusing.

6.2. Isoelectric Focusing

Isoelectric focusing (IEF), was performed using the Immobiline® DryStrip Kit (Pharmacia BioTech), following the procedure described in the manufacturer's instructions, *see* Instructions for Immobiline® DryStrip Kit, Pharmacia, # 18-1038-63, Edition AB (incorporated herein by reference in its entirety). Immobilized pH Gradient (IPG) strips (18cm, pH 3-10 non-linear strips; Pharmacia Cat. # 17-1235-01) were rehydrated overnight at 20°C in a solution of 8M urea, 2% (w/v) CHAPS, 10mM DTT, 2% (v/v) Resolytes 3.5-10, as described in the Immobiline DryStrip Users Manual. For IEF, 50µl of supernatant (prepared as above) was loaded onto a strip, with the cup-loading units being placed at the

basic end of the strip. The loaded gels were then covered with mineral oil (Pharmacia 17-3335-01) and a voltage was immediately applied to the strips according to the following profile, using a Pharmacia EPS3500XL power supply (Cat T9-3500-01):

Initial voltage = 300V for 2 hrs
Linear Ramp from 300V to 3500V over 3hrs
Hold at 3500V for 19hrs

For all stages of the process, the current limit was set to 10mA for 12 gels, and the wattage limit to 5W. The temperature was held at 20°C throughout the run.

6.3. Gel Equilibration and SDS-PAGE 6.3. Gel Equilibration and SDS-PAGE

After the final 19hr step, the strips were immediately removed and immersed for 10 mins at 20°C in a first solution of the following composition: 6M urea; 2% (w/v) DTT; 2% (w/v) SDS; 30% (v/v) glycerol (Fluka 49767); 0.05M Tris/HCl, pH 6.8 (Sigma Cat T-1503). The strips were removed from the first solution and immersed for 10 mins at 20°C in a second solution of the following composition: 6M urea; 2% (w/v) iodoacetamide (Sigma I-6125); 2% (w/v) SDS; 30% (v/v) glycerol; 0.05M Tris/HCl, pH 6.8. After removal from the second solution, the strips were loaded onto supported gels for SDS-PAGE according to Hochstrasser et al., 1988, Analytical Biochemistry 173: 412-423 (incorporated herein by reference in its entirety), with modifications as specified below.

6.4. Preparation of supported gels 6.4. Preparation of supported gels

The gels were cast between two glass plates of the following dimensions: 23cm wide x 24cm long (back plate); 23cm wide x 24cm long with a 2cm deep notch in the central 19cm (front plate). To promote covalent attachment of SDS-PAGE gels, the back plate was treated with a 0.4% solution of γ -methacryl-oxypopyltrimethoxysilane in ethanol (BindSilane™; Pharmacia Cat. # 17-1330-01). The front plate was treated with RepelSilane™ (Pharmacia Cat. # 17-1332-01) to reduce adhesion of the gel. Excess reagent was removed by washing with water, and the plates were allowed to dry. At this stage, both as identification for the gel, and as a marker to identify the coated face of the plate, an adhesive bar-code was attached to the back plate in a position such that it would not come into contact with the gel matrix.

The dried plates were assembled into a casting box with a capacity of 13 gel sandwiches. The top and bottom plates of each sandwich were spaced by means of 1mm thick spacers, 2.5 cm wide. The sandwiches were interleaved with acetate sheets to facilitate separation of the sandwiches after gel polymerization. Casting was then carried out according to Hochstrasser et al., *op. cit.*

A 9-16% linear polyacrylamide gradient was cast, extending up to a point 2cm below the level of the notch in the front plate, using the Angelique gradient casting system (Large Scale Biology). Stock solutions were as follows. Acrylamide (40% in water) was from Serva (Cat. # 10677). The cross-linking agent was PDA (BioRad 161-0202), at a concentration of 2.6% (w/w) of the total starting monomer content. The gel buffer was 0.375M Tris/HCl, pH 8.8. The polymerization catalyst was 0.05% (v/v) TEMED (BioRad 161-0801), and the initiator was 0.1% (w/v) APS (BioRad 161-0700). No SDS was included in the gel and no stacking gel was used. The cast gels were allowed to polymerize at 20°C overnight, and then stored at 4°C in sealed polyethylene bags with 6ml of gel buffer, and were used within 4 weeks.

6.5. SDS-PAGE 6.5. SDS-PAGE

A solution of 0.5% (w/v) agarose (Fluka Cat 05075) was prepared in running buffer (0.025M Tris, 0.198M glycine (Fluka 50050), 1% (w/v) SDS, supplemented by a trace of bromophenol blue). The agarose suspension was heated to 70°C with stirring, until the agarose had dissolved. The top of the supported 2nd D gel was filled with the agarose solution, and the equilibrated strip was placed into the agarose, and tapped gently with a palette knife until the gel was intimately in contact with the 2nd D gel. The gels were placed in the 2nd D running tank, as described by Amess et al., 1995, Electrophoresis 16: 1255-1267 (incorporated herein by reference in its entirety). The tank was filled with running buffer (as above) until the level of the buffer was just higher than the top of the region of the 2nd D gels which contained polyacrylamide, so as to achieve efficient cooling of the active gel area. Running buffer was added to the top buffer compartments formed by the gels, and then voltage was applied immediately to the gels using a Consort E-833 power supply. For 1 hour, the gels were run at 20mA/gel. The wattage limit was set to 150W for a tank containing 6 gels, and the voltage limit was set to 600V. After 1 hour, the gels were then run at 40mA/gel, with the same voltage and wattage limits as before, until the bromophenol

blue line was 0.5cm from the bottom of the gel. The temperature of the buffer was held at 10°C throughout the run.

6.6. Staining 6.6. Staining

Upon completion of the electrophoresis run, the gels were immediately removed from the tank for fixation. The top plate of the gel cassette was carefully removed, leaving the gel bonded to the bottom plate. The bottom plate with its attached gel was then placed into a staining apparatus, which can accommodate 12 gels. The gels were completely immersed in fixative solution of 40% (v/v) ethanol (BDH 28719), 10% (v/v) acetic acid (BDH 100016X), 50% (v/v) water (MilliQ-Millipore), which was continuously circulated over the gels. After an overnight incubation, the fixative was drained from the tank, and the gels were primed by immersion in 7.5% (v/v) acetic acid, 0.05% (w/v) SDS, 92.5% (v/v) water for 30 mins. The priming solution was then drained, and the gels were stained by complete immersion in a staining solution for 4 hours. A solution of fluorescent dye was prepared by diluting Sypro Red (Molecular Probes, Inc., Eugene, Oregon) according to the manufacturer's instructions; this diluted solution was filtered under vacuum through a 0.4µm filter.

6.7. Imaging of the gel 6.7. Imaging of the gel

A computer-readable output was produced by imaging the fluorescently stained gels with a Storm scanner (Molecular Dynamics, Sunnyvale, California) according to the manufacturer's instructions, (*see* Storm User's Guide, 1995, Version 4.0, Part No. 149-355, incorporated herein by reference in its entirety) with modifications as described below. The gels were removed from the stain, rinsed with water briefly, and imaged on the Storm Scanner, in Red Fluorescence mode with a PMT setting of 1000V, and a resolution of 200 µm. Since the gel was rigidly bonded to a glass plate, the gel was held in contact with the scanner bed during imaging. To avoid interference patterns arising from non-uniform contact between the gel and the scanner bed, a film of water was introduced under the gel, taking care to avoid air pockets. Moreover, the gel was placed in a frame provided with two fluorescent buttons that were imaged together with the gel to provide reference points (designated M1 and M2) for determining the x,y coordinates of other features detected in the gel. A matched frame was provided on a robotic gel excisor in order to preserve

accurate alignment of the gel. After imaging, the gels were sealed in polyethylene bags containing a small volume of staining solution, and then stored at 4°C.

6.8. Digital Analysis of the Data 6.8. Digital Analysis of the Data

The data were processed as described in U.S. Application No. 08/980,574, Sections 5.4 and 5.5 (incorporated herein by reference), as set forth more particularly below.

6.8.1. Computer Analysis Of The Detector Output

The output from the scanner was first processed using the MELANIE® II 2D PAGE analysis program (Release 2.2, 1997, BioRad Laboratories, Hercules, California, Cat. # 170-7566) to autodetect the registration points, M1 and M2; to autocrop the images (*i.e.*, to eliminate signals originating from areas of the scanned image lying outside the boundaries of the gel, *e.g.*, the reference frame); to filter out artifacts due to dust; to detect and quantify features; and to create image files in GIF format. Features were detected using the following parameters:

Smooths =2
Laplacian threshold 50
Partials threshold 1
Saturation = 100
Peakedness = 0
Minimum Perimeter = 10

6.9. Assignment of pI and MW Values

Images were evaluated to reject images which had gross abnormalities, or were of too low a loading or overall image intensity, or were of too poor a resolution, or where duplicates were too dissimilar. If one image of a duplicate was rejected then the other image belonging to the duplicate was also rejected regardless of image quality. Samples that were rejected were scheduled for repeat analysis.

Landmark identification was used to determine the pI and MW values of features detected in the images. This process involves the identification of certain proteins which are expected to be found in any given biological sample. As these common proteins exhibit an identical isoelectric point and molecular weight from sample to sample, they can be used as standards; this process also corrects for any possible gel variation or distortion.

From the dataset of normal serum gels, a gel was arbitrarily chosen as the Primary Master Gel. Landmark features were then identified by comparing the features detected in this Primary Master Gel with features previously identified on 2D electrophoresis of normal human serum. (see Bjellqvist et al., 1993, Electrophoresis 14: 1357-1365; incorporated herein by reference in its entirety).

Fourteen landmark features, designated PL1 to PL12 and PL15 to PL16, were identified in the Primary Master Gel. These landmark features are identified in Figure 1 and were assigned the pI and/or MW values indicated in

Table VII. Landmark Features used in this study

Name	pI	MW (kd)	Name	pI	MW (kd)
PL1	None	186,073	PL8	6.47	47,195
PL2	6.20	100,000	PL9	5.29	43,541
PL3	4.73	93,708	PL10	5.22	23,000
PL4	5.13	73,465	PL11	4.47	25,183
PL5	4.97	52,739	PL12	5.52	13,800
PL6	4.10	None	PL15	7.80	36,962
PL7	4.80	40,997	PL16	8.58	None

As many of these landmarks as possible were identified in each gel image in the dataset.

All features in the Master gel were then assigned a pI value by linear interpolation/extrapolation (using the MELANIE II software) to the pI of the two nearest landmarks that had been assigned a pI value, and were assigned a MW value by linear interpolation/extrapolation (using the MELANIE II software) to the MW of the two nearest landmarks that had been assigned a MW value. Each feature was also labelled with a unique number known as its Molecular Cluster Index (or MCI).

Secondary Master gels were chosen for both the cirrhosis gels and the HCC gels. Features in these gels were paired with common features in the Master gel, using the algorithm supplied with the MELANIE II software, as described at Section A, pp. 8-10 of the MELANIE II 2D PAGE (Release 2.2) User Manual (The Melanie Group, Geneva, Switzerland). Features that have been paired are linked to the corresponding MCI, and hence to an associated pI and MW value. Unpaired features present in these secondary master gels were assigned pI and MW values by linear interpolation/extrapolation (using the MELANIE II software) with respect to pI and MW of the landmarks. Additional unique entries were then created in the MCI for these features.

6.9.1. Construction of Profiles

6.9.1. Construction of Profiles

All gels in the dataset were now matched to the Primary and Secondary Master Gels, and paired features were linked to the corresponding entries in the Molecular Cluster Index.

Duplicate gels were then aligned via the landmarks and a matching process performed so as to pair identical spots on the duplicate gels. This provided increased assurance that subsequently measured isoelectric points and molecular weights were accurate, as paired spots demonstrated the reproducibility of the separation and also filtered out artefacts.

A measurement of the intensity of each protein spot was taken and stored. Each protein spot was assigned an identification code and matched to a spot on the Master gel.

The end result of this aspect of the analysis was the generation, for each duplicate set of gels representing a single serum sample, of a digital profile which contained, for each

identified spot: 1) a unique arbitrary identification code, 2) the x,y coordinates, 3) the isoelectric point, 4) the molecular weight, 5) the signal value, 6) the standard deviation for each of the preceding measurements, and 7) a pointer to the MCI of the spot on the master gel to which this spot was matched. By virtue of the Laboratory Information Management System (LIMS), this profile was traceable to the actual stored gel from which it was generated, so that proteins identified by computer analysis of gel profile databases could be retrieved. The LIMS also permitted the profile to be traced back to the original sample or patient.

6.9.2. Cross-Matching Between Samples

6.9.2. Cross-Matching

Between Samples

Once the profile was generated, analysis was directed toward the selection of interesting proteins. Each significant feature in a profile was assigned an index, the "Molecular Cluster Index" (MCI) that identifies the feature in all gels and that serves as a pointer to parameters (1) to (7) above of the feature. A molecular cluster table was generated from the master gel for each sample type (*i.e.* hepatoma serum and cirrhosis serum). Gels from all other samples of the same type were matched with the relevant primary and secondary master gels. The digital profiles for each sample were then annotated by adding, for each matched feature, the MCI assigned to that feature in the master profile.

6.9.3. Differential Analysis of the Profiles

Within each sample set (hepatoma serum or cirrhosis serum), the profiles were analyzed to identify and select those features present in at least 50% of the profiles. These selected features were then assembled into a hepatoma serum feature set and a cirrhosis serum feature set. Matching features of each feature set were then compared to identify those features showing at least a 2-fold difference in mean intensity between hepatoma serum and cirrhosis serum. Differentially present features were identified as Hepatoma-Diagnostic Features (HFs).

6.9.4. Statistical Analysis Of HFs 6.9.4. Statistical Analysis Of HFs

For each HF, a statistical analysis was performed using Student's t-test to compare

the distribution of signal intensities for that feature in the 33 hepatoma serum profiles and in the 19 cirrhosis serum profiles. A p value was derived for each HF.

6.10. Recovery and analysis of selected proteins 6.10. Recovery and analysis of selected proteins

Proteins in HFs were robotically excised and processed to generate tryptic peptides using the Preferred Technology as described in U.S. Application No. 08/980,574, which is incorporated herein by reference in its entirety. Partial amino acid sequences of these peptides were determined by mass spectroscopy, using de novo sequencing.

6.11. Results 6.11. Results

These initial experiments identified 17 features that were decreased and 44 features that were increased in hepatoma serum as compared with cirrhosis serum. Details of these HFs and a p value for each are provided in Tables I and II. Each HF was differentially present in hepatoma serum as compared with non-hepatoma serum ($p < 0.1$). For some preferred HFs (HF-1, HF-3, HF-10, HF-15, HF-16, HF-17, HF-18, HF-19, HF-20, HF-21, HF-23, HF-24, HF-25, HF-26, HF-28, HF-29, HF-31, HF-32, HF-33, HF-34, HF-36, HF-37, HF-38, HF-39, HF-40, HF-42, HF-44, HF-46, HF-47, HF-48, HF-49, HF-51, HF-52, HF-53, HF-54, HF-55, HF-56, HF-59, HF-60, HF-63, HF-75, HF-84, HF-85, HF-89, HF-91, HF-97, HF-100, HF-103, HF-109, HF-110, HF-112, HF-113, HF-120, HF-121, HF-122 and HF-124), the difference was more significant ($p \leq 0.01$), and for certain highly preferred HFs (HF-1, HF-17, HF-18, HF-20, HF-21, HF-23, HF-24, HF-25, HF-28, HF-29, HF-31, HF-33, HF-34, HF-36, HF-39, HF-44, HF-51, HF-52, HF-54, HF-55, HF-59, HF-60, HF-75, HF-84, HF-85, HF-89, HF-91, HF-97, HF-110, HF-113, HF-120, HF-121, HF-122 and HF-124), the difference was still more significant ($p \leq 0.001$).

Partial amino acid sequences were determined for the differentially present HPIs in these HFs. Details of these HPIs are provided in Tables III and IV. Computer searches of public databases identified at least 2 HPIs for which neither the partial amino acid sequence, nor any oligonucleotide encoding such a peptide sequence, was described in any public database examined. Table IV illustrates that several HPIs are isoforms of the same protein. For example, HPI-2, HPI-6, HPI-8, HPI-14, HPI-15, HPI-17 and HPI-18 are isoforms of complement factor 4; HPI-4, HPI-5 and HPI-12 are isoforms of complement factor 3; and

HPI-19, HPI-20 and HPI-21 are isoforms of ceruloplasmin. These isoforms are thought to arise from differences in post-translational processing (e.g., glycosylation, phosphorylation, acylation or minimal proteolysis).

6.12: Preparation of Immobilised Antibody Hi-Trap Triple Column Assemblies

Removal of albumin, haptoglobin, transferrin, alpha-1-antitrypsin alpha-2-macroglobulin and immunoglobulin G (IgG) from human serum ('serum depletion') is achieved by performing an affinity chromatography purification step where the sample is passed through a series of 'Hi-Trap' columns which contain immobilised antibodies to selectively remove albumin, haptoglobin, transferrin, alpha-1-antitrypsin alpha-2-macroglobulin and protein G to selectively remove immunoglobulin G. Two affinity columns in a tandem assembly are prepared by coupling antibodies to protein G-sepharose contained in Hi-Trap columns (Protein G-Sepharose Hi-Trap columns (1 ml) Pharmacia Cat. No. 17-0404-01). This is done by circulating the following solutions sequentially through the columns:

1. Dulbecco's Phosphate Buffered Saline (Gibco BRL Cat. No. 14190-094)
2. concentrated antibody solution
3. 200 mM sodium carbonate buffer, pH 8.35
4. Cross-Linking Solution (200 mM sodium carbonate buffer, pH 8.35, 20 mM dimethylpimelimidate)
5. 500 mM ethanolamine, 500 mM NaCl

A third (un-derivatised) protein G Hi-Trap column is then attached to the lower end of the tandem column assembly.

The chromatographic procedure is automated using an Akta Fast Protein Liquid Chromatography (FPLC) System such that a series of up to seven runs can be performed sequentially. The samples are passed through the series of 3 Hi-Trap columns in which the affinity chromatography media selectively bind the above proteins thereby removing them from the sample. Typically fractions (3 ml per tube) are collected of unbound material ('Flowthru fractions') that elutes through the column during column loading and washing stages and of bound proteins ('Bound/Eluted fractions') that are eluted by step elution with

Immunopure Gentle Ag/Ab Elution Buffer (Pierce Cat. No. 21013). The eluate containing unbound material is collected in fractions which are pooled, desalted/concentrated by centrifugal ultrafiltration and stored to await further analysis by 2D PAGE

The present invention is not to be limited in scope by the particular exemplified embodiments, which are intended as illustrations of single aspects of the invention. Indeed, various modifications of the invention in addition to those enumerated herein will be apparent to those skilled in the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

All publications cited herein are incorporated by reference in their entirety.

CLAIMS

1. A method for screening, diagnosis or prognosis of hepatoma in a human subject or for monitoring the effect of an anti-hepatoma drug or therapy administered to a human subject, comprising:

(a) analyzing a sample of serum or plasma from the subject by two-dimensional electrophoresis to separate a plurality of proteins according to isoelectric point and electrophoretic mobility; and

(b) quantitatively detecting at least one of the following Hepatoma-Diagnostic Features (HF's): HF-57, HF-58, HF-59, HF-60, HF-61, HF-62, HF-63, HF-64, HF-65, HF-66, HF-67, HF-68, HF-69, HF-70, HF-71, HF-72, HF-73, HF-74, HF-75, HF-76, HF-77, HF-78, HF-79, HF-80, HF-81, HF-82, HF-83, HF-84, HF-85, HF-86, HF-87, HF-88, HF-89, HF-90, HF-91, HF-92, HF-93, HF-94, HF-95, HF-96, HF-97, HF-98, HF-99, HF-100, HF-101, HF-102, HF-103, HF-104, HF-105, HF-106, HF-107, HF-108, HF-109, HF-110, HF-111, HF-112, HF-113, HF-114, HF-115, HF-116, HF-117, HF-118, HF-119, HF-120, HF-121, HF-122, HF-123, HF-124, HF-125, HF-126, HF-127, HF-128, HF-129, HF-130, HF-131, HF-132, HF-133, HF-134, HF-135, HF-136, HF-137, HF-138, HF-139, HF-140, HF-141; and, optionally at least one of the following Hepatoma-Diagnostic Features: HF-1, HF-2, HF-3, HF-4, HF-5, HF-6, HF-7, HF-8, HF-9, HF-10, HF-11, HF-12, HF-13, HF-14, HF-15, HF-16, HF-17, HF-18, HF-19, HF-20, HF-21, HF-22, HF-23, HF-24, HF-25, HF-26, HF-27, HF-28, HF-29, HF-30, HF-31, HF-32, HF-33, HF-34, HF-35, HF-36, HF-37, HF-38, HF-39, HF-40, HF-41, HF-42, HF-43, HF-44, HF-45, HF-46, HF-47, HF-48, HF-49, HF-50, HF-51, HF-52, HF-53, HF-54, HF-55, HF-56.

2. The method according to claim 1, wherein step (b) comprises quantitatively detecting at least one of the following HFs: , HF-59, HF-60, HF-63, HF-75, HF-84, HF-85, HF-89, HF-91, HF-97, HF-100, HF-103, HF-109, HF-110, HF-112, HF-113, HF-120, HF-121, HF-122 and HF-124; and optionally at least one of the following HFs: HF-1, HF-3, HF-10, HF-15, HF-16, HF-17, HF-18, HF-19, HF-20, HF-21, HF-23, HF-24, HF-25, HF-26, HF-28, HF-29, HF-31, HF-32, HF-33, HF-34, HF-36, HF-37, HF-38, HF-39, HF-40, HF-42, HF-44, HF-46, HF-47, HF-48, HF-49, HF-51, HF-52, HF-53, HF-54, HF-55, HF-56.

3. The method according to claim 2, wherein step (b) comprises quantitatively detecting at least one of the following HFs: , HF-60, HF-75, HF-84, HF-85, HF-89, HF-91, HF-97, HF-110, HF-113, HF-120, HF-121, HF-122 and HF-124; and optionally at least one of the following HFs: HF-17, HF-18, HF-20, HF-23, HF-24, HF-25, HF-29, HF-33, HF-34, HF-39, HF-44, HF-55.

4. The method according to claims 1, 2 or 3, wherein step (a) comprises isoelectric focussing followed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).

5. A method for screening, diagnosis or prognosis of hepatoma in a subject or for monitoring the effect of an anti-hepatoma drug or therapy administered to a subject, comprising:

(a) in a sample of serum or plasma from the subject, quantitatively detecting at least one of the following Hepatoma-Diagnostic Protein Isoforms (HPIs): . HPI-23, HPI-24, HPI-

25, HPI-26 and HPI-27; and optionally at least one of the following HPis:HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22

6. The method according to claim 5, wherein the step of quantitatively detecting comprises testing at least one aliquot of the sample, said step of testing comprising:

(a) contacting the aliquot with an antibody that is immunospecific for a preselected HPI; and

(b) detecting whether binding has occurred between the antibody and at least one species in the aliquot.

7. The method according to claim 6, wherein the antibody is a monoclonal antibody.

8. The method according to claim 6, wherein the step of quantitatively detecting comprises testing a plurality of aliquots with a plurality of antibodies.

9. The method according to claim 8, wherein the antibodies are monoclonal antibodies.

10. A preparation comprising at least one of the following isolated Hepatoma-Diagnostic Protein Isoforms (HPis): HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27; and optionally at least one of the following HPis: HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22.

11. A kit comprising the preparation of claim 10.
 12. A kit comprising a plurality of preparations of claim 10.
 13. A preparation comprising an isolated human protein, said protein comprising a peptide having the following sequence : AETTDF or AETTDM.
 14. The preparation according to claim 13 wherein the protein has an isoelectric point (pI) of about 7.44 and an apparent molecular weight (MW) of about 63882.
 15. The preparation according to claim 14, wherein the pI is within 10% of 7.44 and the MW is within 10% of 63882.
-
16. The preparation according to claim 14, wherein the pI is within 5% of 7.44 and the MW is within 5% of 63882.
 17. The preparation according to claim 14, wherein the pI is within 1% of 7.44 and the MW is within 1% of 63882.
 18. A preparation comprising an isolated human protein, said protein comprising at least one peptide having the following sequence : LWLGTTT, LDALGTTT, LADLGTTT, LGELGTTT, LEGLGTTT, LVSLGTTT, LSVLGTTT, IWLGTTT, IDALGTTT,

IADLGTTT, IGELGTTT, IEGLGTTT, IVSLGTTT, ISVLGTTT, LWIGTTT,
LDAIGTTT, LADIGTTT, LGEIGTTT, LEGIGTTT, LVSIGTTT, LSVIGTTT, IWIGTTT,
IDAIGTTT, IADIGTTT, IGEIGTTT, IEGIGTTT, IVSIGTTT, or ISVIGTTT.

19. The preparation according to claim 18 wherein the protein has an isoelectric point (pI) of about 5.29 and an apparent molecular weight (MW) of about 43541.

20. The preparation according to claim 19, wherein the pI is within 10% of 5.29 and the MW is within 10% of 43541.

21. The preparation according to claim 19, wherein the pI is within 5% of 5.29 and the MW is within 5% of 43541.

22. The preparation according to claim 19, wherein the pI is within 1% of 5.29 and the MW is within 1% of 43541.

23. An antibody capable of immunospecific binding to one of the following Hepatoma-Diagnostic Protein Isoforms (HPIs): HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27.

24. The antibody of claim 23, which is a monoclonal antibody.

25. The antibody of claim 23 or 24, which binds to the HPI with greater affinity than to another isoform of the HPI.

26. The antibody of claim 23 which binds to the HPI with greater affinity than to any other isoform of the HPI.

27. A kit comprising one or more antibodies as claimed in claim 25 or claim 26.

28. A pharmaceutical composition comprising a therapeutically effective amount of an antibody as claimed in claim 13 or claim 14 and optionally a pharmaceutically acceptable carrier.

29. A pharmaceutical composition comprising:

a therapeutically effective amount of a fragment or derivative of an antibody as claimed in claim 23 or claim 24, said fragment or derivative containing the binding domain of the antibody; and optionally
a pharmaceutically acceptable carrier.

30. A method of treating or preventing hepatoma comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of a nucleic acid encoding one of the following Hepatoma-Associated Protein Isoforms (HPIs): HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14,

HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27.

31. A method of treating or preventing hepatoma comprising administering to a subject in need of such treatment or prevention a therapeutically effective amount of a nucleic acid that inhibits the function of one or more of the following Hepatoma -Associated Protein Isoforms (HPIs): HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27.

32. The use of a therapeutically effective amount of a nucleic acid encoding one of the following Hepatoma -Associated Protein Isoforms (HPIs): HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27 in the manufacture of a medicament for use in the prevention or treatment of breast cancer.

33. The use of a therapeutically effective amount of a nucleic acid that inhibits the function of one or more of the following Hepatoma -Associated Protein Isoforms (HPIs): HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27 in the manufacture of a medicament for use in the prevention or treatment of breast cancer.

34. The method of claim 31 or claim 33, wherein the nucleic acid is a HPI antisense nucleic acid or ribozyme.
35. A method of screening for agents that interact with a HPI, a HPI fragment, or a HPI-related polypeptide, said method comprising:
- (a) contacting a HPI, a biologically active portion of a HPI, or a HPI-related polypeptide with a candidate agent; and
 - (b) determining whether or not the candidate agent interacts with the HPI, the HPI fragment, or the HPI-related polypeptide.
36. The method of claim 33, wherein the HPI, the HPI fragment, or the HPI-related polypeptide is expressed by cells.
-
37. The method of claim 34, wherein the cells express a recombinant HPI, a recombinant HPI fragment, or a recombinant HPI-related polypeptide.
38. A method of screening for agents that modulate the expression or activity of a HPI or a HPI-related polypeptide comprising:
- (a) contacting a first population of cells expressing a HPI or a HPI-related polypeptide with a candidate agent;

- (b) contacting a second population of cells expressing said HPI or said HPI-related polypeptide with a control agent; and
- (c) comparing the level of said HPI or said HPI-related polypeptide or mRNA encoding said HPI or said HPI-related polypeptide in the first and second populations of cells, or comparing the level of induction of a cellular second messenger in the first and second populations of cells.

39. The method of claim 36, wherein the level of said HPI or said HPI-related polypeptide, mRNA encoding said HPI or said HPI-related polypeptide, or said cellular second messenger is greater in the first population of cells than in the second population of cells.

40. The method of claim 36, wherein the level of said HPI or said HPI-related polypeptide, mRNA encoding said HPI or said HPI-related polypeptide, or said cellular second messenger is less in the first population of cells than in the second population of cells.

41. A method of screening for or identifying agents that modulate the expression or activity of a HPI or a HPI-related polypeptide comprising:

- (a) administering a candidate agent to a first mammal or group of mammals;
- (b) administering a control agent to a second mammal or group of mammals;

and

(c) comparing the level of expression of the HPI or the HPI-related polypeptide or of mRNA encoding the HPI or the HPI-related polypeptide in the first and second groups, or comparing the level of induction of a cellular second messenger in the first and second groups.

42. The method of claim 41, wherein the mammals are animal models for breast cancer.

43. The method of claim 41 or 42, wherein the level of expression of said HPI or said HPI-related polypeptide, mRNA encoding said HPI or said HPI-related polypeptide, or of said cellular second messenger is greater in the first group than in the second group.

44. The method of claim 41 or 42, wherein the level of expression of said HPI or said HPI-related polypeptide, mRNA encoding said HPI or said HPI-related polypeptide, or of said cellular second messenger is less than in the first group than in the second group.

45. The method of claim 41, wherein the levels of said HPI or said HPI-related polypeptide, mRNA encoding said HPI or said HPI-related polypeptide, or of said cellular second messenger in the first and second groups are further compared to the level of said HPI or said HPI-related polypeptide or said mRNA encoding said HPI or said HPI-related polypeptide in normal control mammals.

46. The method of claim 41, wherein administration of said candidate agent modulates the level of said HPI or said HPI-related polypeptide, or said mRNA encoding said HPI or said HPI-related polypeptide, or said cellular second messenger in the first group towards the levels of said HPI or said HPI-related polypeptide or said mRNA or said cellular second messenger in the second group.

47. The method of any one of claims 41 to 46, wherein said mammals are human subjects having hepatoma.

48. A method of screening for or identifying agents that interact with a HPI or a HPI-related polypeptide, comprising

(a) contacting a candidate agent with the HPI or the HPI-related polypeptide,
and

(b) quantitatively detecting binding, if any, between the agent and the HPI or the HPI-related polypeptide.

49. A method of screening for or identifying agents that modulate the activity of a HPI or a HPI-related polypeptide, comprising

(a) in a first aliquot, contacting a candidate agent with the HPI or the HPI-related polypeptide, and

(b) comparing the activity of the HPI or the HPI-related polypeptide in the first

aliquot after addition of the candidate agent with the activity of the HPI or the HPI-related polypeptide in a control aliquot, or with a previously determined reference range.

50. The method according to claim 48 or 49, wherein the HPI or the HPI-related polypeptide is recombinant protein.
51. The method according to any one of claims 48 or 49, wherein the BPI or the BPI-related polypeptide is immobilized on a solid phase.
52. An isolated nucleic acid molecule that hybridizes to a nucleotide sequence encoding HPI-13 or HPI-21 or their complements.
-
53. An isolated nucleic acid molecule that hybridizes to a nucleotide sequence encoding at least 10 consecutive amino acids of HPI-13 or HPI-21 or their complements.
54. A vector comprising the nucleic acid molecule of claim 52 or 53.
55. A host cell comprising the vector of claim 54.

56. A host cell genetically engineered to express the nucleic acid molecule of claim 52 or 53.

57. A method for screening, diagnosis or prognosis of breast cancer in a subject or for monitoring the effect of an anti-breast cancer drug or therapy administered to a subject, comprising:

(a) contacting at least one oligonucleotide probe comprising 10 or more consecutive nucleotides complementary to a nucleotide sequence encoding a HPI chosen from HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27 with an RNA obtained from a biological sample from the subject or with cDNA copied from the RNA wherein

said contacting occurs under conditions that permit hybridization of the probe to the nucleotide sequence if present;

(b) detecting hybridization, if any, between the probe and the nucleotide sequence; and

(c) comparing the hybridization, if any, detected in step (b) with the hybridization detected in a control sample, or with a previously determined reference range.

58. The method of claim 57, wherein step (a) comprises contacting a plurality of oligonucleotide probes comprising 10 or more consecutive nucleotides complementary to a

nucleotide sequence encoding a HPI chosen from HPI-1, HPI-2, HPI-3, HPI-4, HPI-5, HPI-6, HPI-8, HPI-9, HPI-10, HPI-11, HPI-12, HPI-13, HPI-14, HPI-15, HPI-16, HPI-17, HPI-18, HPI-19, HPI-20, HPI-21, HPI-22, HPI-23, HPI-24, HPI-25, HPI-26 and HPI-27 with an RNA obtained from a biological sample from the subject or with cDNA copied from the RNA wherein said contacting occurs under conditions that permit hybridization of the probe to the nucleotide sequence if present.

59. The method of claim 57, wherein step (a) includes the step of hybridizing the nucleotide sequence to a DNA array, wherein one or more members of the array are the probes complementary to a plurality of nucleotide sequences encoding distinct HPIs.

60. An isolated nucleic acid molecule that hybridizes under highly stringent conditions or moderately stringent conditions to the following nucleic acid sequence:

GCCGAGACCACCGACTTC or GCCGAGACCACCGACATG.

61. An isolated nucleic acid molecule that hybridizes under highly stringent conditions or moderately stringent conditions to the following nucleic acid sequence:

GCNGARACNACNGAYTTY or GCNGARACNACNGAYATG.

62. An isolated nucleic acid molecule that hybridizes under highly stringent conditions or moderately stringent conditions to the following nucleic acid sequence:

CTGTGGCTGGGCACCACCCGC, CTGGACGCCCTGGGCACCACCCGC,
CTGGCCGACCTGGGCACCACCCGC, CTGGGCGAGCTGGGCACCACCCGC,
CTGGAGGCCCTGGGCACCACCCGC, CTGGTGAGCCTGGGCACCACCCGC,
CTGAGCGTGCTGGGCACCACCCGC, ATCTGGCTGGGCACCACCCGC,
ATCGACGCCCTGGGCACCACCCGC, ATCGCCGACCTGGGCACCACCCGC,
ATCGGCGAGCTGGGCACCACCCGC, ATCGAGGCCCTGGGCACCACCCGC,
ATCGTGAGCCTGGGCACCACCCGC, ATCAGCGTGCTGGGCACCACCCGC,
CTGTGGATCGGCACCACCCGC, CTGGACGCCATCGGCACCACCCGC,
CTGGCCGACATCGGCACCACCCGC, CTGGGCGAGATCGGCACCACCCGC,
CTGGAGGCCATCGGCACCACCCGC, CTGGTGAGCATCGGCACCACCCGC,
CTGAGCGTGATCGGCACCACCCGC, CTGTGGATCGGCACCACCCGC,
ATCGACGCCATCGGCACCACCCGC, ATCGCCGACATCGGCACCACCCGC,
ATCGGCGAGATCGGCACCACCCGC, ATCGAGGCCATCGGCACCACCCGC,
ATCGTGAGCATCGGCACCACCCGC, or ATCAGCGTGATCGGCACCACCCGC.

63. An isolated nucleic acid molecule that hybridizes under highly stringent conditions or moderately stringent conditions to the following nucleic acid sequence:

YTNTGGYTNGGNACNACNMGN, YTN GAYGCNYTNGGNACNACNMGN,
YTN GCNGAYYTNGGNACNACNMGN, YTN GNGARYTNGGNACNACNMGN,
YTN GARGGNYTNGGNACNACNMGN, YTN GTNWSNYTNGGNACNACNMGN,
YTN WSNGTNYTNGGNACNACNMGN, ATHTGGYTNGGNACNACNMGN,
ATHGAYGCNYTNGGNACNACNMGN, ATHGCNGAYYTNGGNACNACNMGN,
ATHGGNGARYTNGGNACNACNMGN, ATHGARGGNYTNGGNACNACNMGN,

ATHGTNWSNYTNGGNACNACNMGN, ATHWSNGTNYTNGGNACNACNMGN,
YTNTGGATHGGNACNACNMGN, YTINGAYGCNATHGGNACNACNMGN,
YTINGCNGAYATHGGNACNACNMGN, YTINGGNGARATHGGNACNACNMGN,
YTINGARGGNATHGGNACNACNMGN, YTINGTNWSNATHGGNACNACNMGN,
YTNWSNGTNATHGGNACNACNMGN, ATHTGGATHGGNACNACNMGN,
ATHGAYGCNATHGGNACNACNMGN, ATHGCNGAYATHGGNACNACNMGN,
ATHGGNGARATHGGNACNACNMGN, ATHGARGGNATHGGNACNACNMGN,
ATHGTNWSNATHGGNACNACNMGN, or ATHWSNGTNATHGGNACNACNMGN

64. The use of one or more HFs as defined in claim 1 in screening, diagnosis or prognosis of hepatoma in a human subject or for monitoring the effect of an anti-hepatoma drug.

65. The use of one or more HPIs as defined in claim 5 in screening, diagnosis or prognosis of hepatoma in a human subject or for monitoring the effect of an anti-hepatoma drug.

66. The use of one or more antibodies that is/are immunospecific for one or more of the HPIs defined in claim 5 in screening, diagnosis or prognosis of hepatoma in a human subject or for monitoring the effect of an anti-hepatoma drug.

67. The use as claimed in any one of claims 64 to 66 which is used in combination with an assay or assessment for Hepatitis B and/or Hepatitis C.




FIG. 1

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 February 2001 (22.02.2001)

PCT

(10) International Publication Number
WO 01/13118 A3

(51) International Patent Classification: **G01N 33/574**,
33/561, C12Q 1/68, C07K 14/47, C12N 5/10

Quadrant, Abingdon Science Park, Abingdon OX14 3YS
(GB).

(21) International Application Number: **PCT/GB00/03224**

(72) Inventors; and

(22) International Filing Date: **18 August 2000 (18.08.2000)**

(75) Inventors/Applicants (for US only): **PAREKH, Rajesh,**

(25) Filing Language: **English**

Bhikhu [GB/GB]; Oxford GlycoSciences (UK) Ltd., 10

(26) Publication Language: **English**

Abingdon, Oxon OX14 3YS (GB). PATEL, Thakorbbhai,

(30) Priority Data:
9919597.6 18 August 1999 (18.08.1999) GB

Parshotambhai [GB/GB]; Oxford GlycoSciences (UK)

Ltd., 10 The Quadrant, Barton Lane, Abingdon Science

Park, Abingdon, Oxon OX14 3YS (GB). TOWNSEND,

Robert, Reid [US/GB]; Oxford GlycoSciences (UK)

(71) Applicant (for all designated States except US): **OXFORD**
GLYCOSCIENCES (UK) LIMITED [GB/GB]; 10 The

Ltd., 10 The Quadrant, Barton Lane, Abingdon Science

Park, Abingdon, Oxon OX14 3YS (GB). MOYSES,

Christopher [GB/GB]; Oxford GlycoSciences (UK) Ltd.,

10 The Quadrant, Barton Lane, Abingdon Science

Park, Abingdon, Oxon OX14 3YS (GB). JOHNSON, Philip,

Abingdon, Oxon OX14 3YS (GB).

JOHNSON, Philip,

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).


Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

Abingdon, Oxon OX14 3YS (GB).

[Continued on next page]

(54) Title: **METHODS AND COMPOSITIONS FOR DIAGNOSIS OF HEPATOMA**



(57) Abstract: The present invention provides methods and compositions for screening, diagnosis and prognosis of hepatoma, for monitoring the effectiveness of hepatoma treatment, and for drug development. Hepatoma-Diagnostic Features (HFs), detectable by two-dimensional electrophoresis of serum or plasma are described. The invention further provides Hepatoma-Diagnostic Protein Isoforms (HPIs) detectable in serum or plasma, preparations comprising isolated HPIs, antibodies immunospecific for HPIs, and kits comprising the aforesaid.

WO 01/13118 A3



James [GB/CN]; The Chinese University of Hong Kong, Dept. of Clinical Oncology, Prince of Wales Hospital, Shatin, New Territories, Hong Kong (CN).

(74) Agents: CHAPMAN, Paul, William et al.; Kilburn & Strode, 20 Red Lion Street, London WC1R 4PJ (GB).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:

17 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/GB 00/03224

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 G01N33/574 G01N33/561 C12Q1/68 C07K14/47 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01N C07K C12Q A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, CHEM ABS Data, STRAND, MEDLINE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WIRTH ET AL: "Two-dimensional polyacrylamide gel electrophoresis in experimental hepatocarcinogenesis studies" ELECTROPHORESIS, DE, WEINHEIM, vol. 15, no. 3/04, March 1994 (1994-03), pages 358-371, XP002104803 ISSN: 0173-0835 abstract page 360, left-hand column, line 8 - line 17	1-12, 24-52, 58-60, 65-68
A	EP 0 171 243 A (KYOWA MEDEX CO LTD) 12 February 1986 (1986-02-12) abstract; claims 1,2	1-12, 24-52, 58-60, 65-68

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

14 May 2001

Date of mailing of the international search report

28.05.2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gundlach, B

INTERNATIONAL SEARCH REPORT

Int ional Application No

PCT/GB 00/03224

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 39200 A (UNIV JEFFERSON ;FEITELSON MARK A (US)) 5 August 1999 (1999-08-05) abstract claims 1-21 ---	1-12, 24-52, 58-60, 65-68
A	US 4 558 004 A (HAMMOCK BRUCE D ET AL) 10 December 1985 (1985-12-10) abstract claim 1 ---	1-12, 24-52, 58-60, 65-68
A	EP 0 334 962 A (ORIENTAL YEAST CO LTD) 4 October 1989 (1989-10-04) abstract claims 1,2; table 1 ---	1-12, 24-52, 58-60, 65-68
X	DARABI ALI ET AL: "Differential gene expression in experimental hepatocellular carcinoma induced by woodchuck hepatitis B virus." CANCER LETTERS, vol. 95, no. 1-2, 16 August 1995 (1995-08-16), pages 153-159, XP000978529 ISSN: 0304-3835 abstract page 154, column 2, paragraph 4 -page 156, column 1, paragraph 1 page 156, column 2, paragraph 2 -page 158, column 2, paragraph 1 ---	1,4,65, 68
Y		5-12, 24-52, 58-60, 66-68
X	ABD-EL-FATTAH M ET AL: "KINETICS OF THE ACUTE PHASE REACTION IN RATS AFTER TUMOR TRANSPLANTATION" CANCER RESEARCH, vol. 41, no. 6, 1981, pages 2548-2555, XP000978526 ISSN: 0008-5472 abstract page 1, column 1, paragraph 1 -column 2, paragraph 2 figure 1 page 2553, column 1, paragraphs 2,3 --- -/--	1,4

INTERNATIONAL SEARCH REPORT

Int. l. Application No

PCT/GB 00/03224

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ALTRUDA, F. ET AL: "Structure of the human hemopexin gene and evidence for intron-mediated evolution" J. MOL. EVOL. (1988), 27(2), 102-8, XP000978509 the whole document	5-12, 24-52, 58-60, 66-68
A	ALTRUDA, FIORELLA ET AL: "The primary structure of human hemopexin deduced from cDNA sequence: evidence for internal, repeating homology" NUCLEIC ACIDS RES. (1985), 13(11), 3841-59, XP000971980 abstract	5-12, 24-52, 58-60, 66-68
A	TAKAHASHI, NOBUHIRO ET AL: "Complete amino acid sequence of human hemopexin, the heme-binding protein of serum" PROC. NATL. ACAD. SCI. U. S. A. (1985), 82(1), 73-7, XP000971981 the whole document	5-12, 24-52, 58-60, 66-68
X	US 5 147 638 A (COMP PHILIP C ET AL) 15 September 1992 (1992-09-15) the whole document	10, 24, 25, 30
X	LAPPIN D F ET AL: "Effect of interferon-gamma on complement gene expression in different cell types." BIOCHEMICAL JOURNAL, (1992 JAN 15) 281 (PT 2) 437-42., XP000994508 abstract; table 1	10
X	MATSUGUCHI, TETSUYA ET AL: "Molecular cloning of the cDNA coding for proline-rich protein (PRP): identity of PRP as C4b-binding protein" BIOCHEM. BIOPHYS. RES. COMMUN. (1989), 165(1), 138-44 , XP000993300 abstract	10, 24, 30
X	WO 96 27011 A (GENENTECH INC) 6 September 1996 (1996-09-06) see SEQ ID NO:4 abstract	10, 24, 25, 30

-/--

INTERNATIONAL SEARCH REPORT

Int. Patent Application No
PCT/GB 00/03224

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CHINTALACHARUVU, KOTESWARA R. ET AL: "Divergence of human.alpha.-chain constant region gene sequences. A novel recombinant.alpha.2 gene" J. IMMUNOL. (1994), 152(11), 5299-304 , XP000993299 abstract page 5301, paragraph 4 ----	10,24, 25,30
X	KRATZIN, HARTMUT ET AL: "Structural principles of antibodies. The primary structure of a human monoclonal IgA1-immunoglobulin (myeloma protein Tro), V. The arrangement of the tryptic peptides and a discussion of the complete primary structure of the H-chain" HOPPE-SEYLER'S Z. PHYSIOL. CHEM. (1978), 359(12), 1717-46 , XP001001389 abstract ----	10
X	ULGIATI, DANIELA ET AL: "Comparative analysis of the disease-associated complement C4 gene from the HLA-A1, B8, DR3 haplotype" EXP. CLIN. IMMUNOGENET. (1996), 13(1), 43-54 , XP001001407 abstract ----	10
X	ULGIATI, DANIELA ET AL: "Complete sequence of the complement C4 gene from the HLA-A1, B8, C4A0, C4B1, DR3 haplotype" IMMUNOGENETICS (1996), 43(4), 250-2 , XP001001405 the whole document ----	10
X	YU, C. YUNG: "The complete exon-intron structure of a human complement component C4A gene. DNA sequences, polymorphism, and linkage to the 21-hydroxylase gene" J. IMMUNOL. (1991), 146(3), 1057-66 , XP000993298 the whole document ----	10
X	US 5 175 083 A (MOULDS JOANN M) 29 December 1992 (1992-12-29) the whole document ----	10,24, 25,30
P,A	WO 99 41612 A (JOHNSON PHILIP J ;OXFORD GLYCOSCIENCES UK LTD (GB); MOYSES CHRISTO) 19 August 1999 (1999-08-19) the whole document -----	1-12, 24-52, 58-60, 65-68

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/03224

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☒ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
1-12, 24-52, 58-60, 65-68 (all in part, in so far as they relate to HF(s)
57, 58, 59, 60, 61 and HPI(s) 23, 24, 25, 26, 27)
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: Invention 1: Claims 1,4-12,24-52,58-60,
65-68 (all in part)

Markers and methods for diagnosis of hepatoma involving
HF-57 and HPI-23

2. Claims: Inventions 2-85: Claims 1-68 (all in part)

Markers and methods for diagnosis of hepatoma involving
HF-58, HF-59,, HF-141 as markers

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.1

Although claims 31, 32, and 35 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.1

Rule 39.1(iv) PCT - Method for treatment of the human or animal body by therapy

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int Jonal Application No

PCT/GB 00/03224

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0171243 A	12-02-1986	JP 1970290 C	18-09-1995
		JP 6105257 B	21-12-1994
		JP 61044355 A	04-03-1986
		AU 584346 B	25-05-1989
		AU 4565485 A	13-02-1986
		CA 1260388 A	26-09-1989
		DE 3586614 A	15-10-1992
		DE 3586614 T	08-04-1993
		DK 357185 A	08-02-1986
		US 4791066 A	13-12-1988
WO 9939200 A	05-08-1999	AU 2480799 A	16-08-1999
US 4558004 A	10-12-1985	NONE	
EP 0334962 A	04-10-1989	JP 1065454 A	10-03-1989
		JP 2579497 B	05-02-1997
		CA 1335071 A	04-04-1995
		DE 3853582 D	18-05-1995
		DE 3853582 T	02-11-1995
		WO 8902474 A	23-03-1989
		US 4994374 A	19-02-1991
US 5147638 A	15-09-1992	AT 149842 T	15-03-1997
		AU 639014 B	15-07-1993
		AU 6164390 A	11-03-1991
		CA 2064585 A	05-02-1991
		DE 69030189 D	17-04-1997
		DE 69030189 T	10-07-1997
		EP 0489048 A	10-06-1992
		JP 7029937 B	05-04-1995
		JP 4504264 T	30-07-1992
		WO 9101753 A	21-02-1991
		AT 122057 T	15-05-1995
		AU 4422893 A	27-01-1994
		AU 641634 B	30-09-1993
		AU 4968390 A	01-08-1990
		CA 2006684 A,C	30-06-1990
		DE 68922491 D	08-06-1995
		DE 68922491 T	09-11-1995
		DK 209090 A	30-08-1990
		EP 0407544 A	16-01-1991
		ES 2074562 T	16-09-1995
		FI 101476 B	30-06-1998
		JP 2559537 B	04-12-1996
		JP 3504332 T	26-09-1991
		KR 9402033 B	14-03-1994
		NO 903788 A	29-10-1990
		WO 9007524 A	12-07-1990
		US 5202253 A	13-04-1993
		US 5298599 A	29-03-1994
		US 5336610 A	09-08-1994
WO 9627011 A	06-09-1996	US 5731168 A	24-03-1998
		AU 702737 B	04-03-1999
		AU 4973396 A	18-09-1996
		BR 9607622 A	09-06-1998
		CA 2211459 A	06-09-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int. l. Application No

PCT/GB 00/03224

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9627011 A		CN 1176659 A	18-03-1998
		EP 0812357 A	17-12-1997
		FI 973543 A	28-08-1997
		JP 11500915 T	26-01-1999
		NO 973982 A	03-11-1997
		NZ 303425 A	29-07-1999
		US 5807706 A	15-09-1998
		US 5821333 A	13-10-1998
US 5175083 A	29-12-1992	NONE	
WO 9941612 A	19-08-1999	AU 2534999 A	30-08-1999
		EP 1055126 A	29-11-2000

THIS PAGE BLANK (USPTO)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)